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ABSTRACT   
High-mobility group A1 (HMGA1) proteins are architectural chromatinic 
proteins that are abundantly expressed during embryogenesis and in most 
cancer tissues, but are expressed at low levels or are absent in normal adult 
tissues. Several studies have demonstrated that HMGA1 proteins play a causal 
role in neoplastic cell transformation. HMGA1 has been shown to induce stem 
cell-like properties in colon cancer cells, suggesting that HMGA1 may be a key 
regulator in the maintenance of a stem cell-like state. The aim of this study was 
to investigate the role of these proteins in the control of cancer stem cells 
(CSCs), which have emerged as a preferred target in cancer therapy, because of 
their role in tumor recurrence. First, we observed that HMGA1 is 
overexpressed in colon tumor stem cell (CTSC) lines with respect to normal 
and colon cancer tissues. We demonstrated that the inhibition of HMGA1 
expression in CTSCs increases the percentage of PKH26-positive cells, 
indicating increased stem cell quiescence. Moreover, HMGA1 silencing 
induces a drastic reduction in their self-renewal and sphere-forming efficiency 
(SFE). This effect, together with the finding of an asymmetric NUMB 
distribution in interfered cells, is indicative of the recovery of an asymmetric 
division pattern, characteristic of normal stem cells. Indeed, we have been able 
to demonstrate that HMGA1 negatively regulates p53  and NUMB expression 
at transcriptional level, thereby accounting for their increased expression at 
protein level in CTSC-HMGA1-silenced cells. Indeed, p53 has been recently 
found to regulate the balance between symmetric and asymmetric division; on 
the other hand, NUMB is known for its role as cell fate determinant in stem 
cells and effector in the stabilization of p53.  The HMGA1 transcriptional 
regulation of NUMB and p53 likely accounts for the reduced SFE of silenced 
CTSCs. Preliminary data suggest that targeting HMGA1 makes resistant 
CTSCs more sensitive to chemotherapeutic agents. Therefore, our data indicate 
a critical role for HMGA1 in regulating both self-renewal and the balance of 
symmetric/asymmetric division in colon CSCs and suggest that blocking 
HMGA1 function may be an effective anti-cancer therapy.  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1. BACKGROUND 
 
1.1. Tumors and Stemness 
 
Cancer arises from a small set of stem cells, or tumor-initiating cells, that differ 
from normal stem cells in their deregulated self-renewal and differentiation 
programs.  
Although researchers had long hypothesized that cancers may arise from stem 
or stem-like cells, it was in 1994 that a stem cell-like population was isolated 
from a human cancer. John Dick and colleagues showed that human acute 
myeloid leukemia (AML) contains a small percentage of cells enriched on the 
basis of cell surface marker expression (CD34+/CD38−) that were capable of 
transferring human AML into immunodeficient hosts. The resulting leukemia 
recapitulates the morphologic and immunophenotypic heterogeneity of the 
original disease, and engrafted blasts were able to reproduce the tumor in 
secondary recipients (Lapidot et al. 1994).  
1.1.1. The CSCs hypotesis  
First studies of AML stem cells laid the foundation for the CSC hypotesis 
which holds that, like normal tissue, cancers are originated by a population of 
stem-like cells that exibit the ability to self-renew as well as differentiate into 
downstrem, non self-renewing progenitors and mature cells. Further these 
interesting findings arose great interest through the discovery of cells with stem 
cell properties in other tumors. So, human CSCs were identified also in solid 
tumors, including breast (Al-Hajj et al. 2003), brain (Singh et al. 2003), colon 
(O'Brien et al. 2007), pancreas (Li et al. 2007), lung, prostate cancer (Collins et 
al. 2005) and melanoma.  
Expression of cell surface markers such as CD44, CD24, CD29, CD90, 
CD133, epithelial-specific antigen (ESA), and aldehyde dehydrogenase1 
(ALDH1) have been used to isolate and enrich CSCs from different tumors 
(Al-Hajj, Wicha et al. 2003), (Singh et al. 2003), (Ginestier et al. 2007). 
Notably, the expression of CSC surface markers is tissue type-specific and 
tumor subtype-specific. For example, CD44+CD24−/low lineage and ALDH+ 
are characteristic of breast CSCs; CD133+ of colon, brain and lung; 
CD34+CD8− of leukemia; CD44+ of head and neck; CD90+ of liver; 
CD44+/CD24+/ESA+ of pancreas CSCs (Ginestier et al. 2007). 
There are several different theories regarding the origin of CSCs ( Fig. 1.1).  
One theory holds that CSCs arise from normal stem/progenitor cells which 
gain the ability to generate tumors when encountering a special genetic 
mutation or environmental alteration. Some CSCs exhibit similarities to normal 
stem/progenitor cells in cellular property, phenotype, function, and even cell 
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surface markers (Li et al. 2007), (Kucia and Ratajczak 2006). Another theory 
suggests that they arise from normal somatic cells which acquire stem-like 
characteristics and malignant behavior through genetic and/or heterotypic 
alterations. For example, cancer cells gain stem-like characteristics through 
epithelial-mesenchymal transition (EMT). The induction of EMT in 
immortalized human mammary epithelial cells results in the acquisition of 
mesenchymal traits and expression of stem-cell markers (Yu et al. 2007) 
(Takahashi et al. 2007). Given the different hypotesis about the origin of CSCs, 
they are often defined preferentially as Tumor Initiating Cells (TICs) to avoid 
confusion. 
 
    
Figure 1.1. Summary scheme of the hypotesis on the CSCs origin. A CSC 
could take origin from a normal stem cell which, after mutations in genes 
involved in the regulation of fundamental cell function such as 
proliferation, differentiation  and self renewal acquire malignant 
properties. Also CSCs could derive from a differentiated cell which gain 
proliferation potential and turns on self-renewal genes resulting in a stem-
like cell (from Are Stem Cells Involved in Cancer? Stem Cell Information 
2011).  
1.1.2. CSCs feautures  
CSCs are defined by the American Association of Cancer Research as “the 
cells within a tumor that possesse the capacity to self-renew and to cause the 
heterogeneous lineages of cancer cells that comprise the tumor". Indeed, CSCs 
    10 
are characterized by some particular features. They are able to generate more 
SCs (self-renewal) and to produce cells that differentiate. Asymmetric cell 
division achieves both tasks, as one progeny retains SC identity and the other 
undergoes rounds of cell division and subsequent post-mitotic differentiation. 
Also, CSCs are responsible of the initiation and the maintainance of tumor 
growth; indeed, in serial transplantation in mice they are able to reproduce the 
tumor with the same molecular  and phenotypic characteristics of the tumor 
from which they derived. Further, CSCs are defined by their unlimited 
proliferation potential. Still debated are the criteria for classifying CSCs and, 
therefore, it has not been possible to definitively define the proportion of CSCs 
subpopulation in a given tumor, the relevance of CSCs to clinical outcome, and 
the origin of CSCs (Yu, Vodyanik et al. 2007)  (Hope et al. 2004). 
1.1.3. CSCs and therapies  
Despite decades of research and many novel therapeutic approaches, cancer 
remains one of the leading causes of mortality in humans at all ages.  New 
drugs are available, but few of these provide a durable response, and even 
fewer can readily eradicate tumors in a small number of malignancies 
(Sakariassen et al. 2007). Surrogate end point parameters such as 'progression-
free survival', 'disease-free survival', or 'recurrence-free survival' reflect the 
temporary pause in the progression of the disease, seldom lasting more than a 
few months. Subsequently, the cancer typically relapses with even more 
aggressive characteristics due to the presence of a bulk of CSCs which, 
because of their intrinsic chemoresistance, are spared and “naturally selected” 
by the routinely used anti-cancer drugs. CSCs  resistance to conventional 
therapies is generally  attributed to specific features such as high levels of 
molecules involved in the DNA damage repair, high expression of drug 
transporters and resistance to apoptosis. After the isolation of CSCs from 
human acute myeloid leukemia (AML), the greatest clinical implication 
evolving around the CSC hypothesis is that one may need to develop targeted 
treatment regimes against the unique CSC population for the cure of cancer 
(Tang et al. 2007).   The identification of biomarkers that distinguish CSCs 
from their normal counterparts and a better understanding of the biological 
processes operating predominantly in the CSC subpopulation would be good 
challenges in the development of specific therapies to eradicate cancer. 
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Figure 1.2. CSCs drug resistance. CSCs are resistant to conventional 
therapies, thereby leading to tumor relapse. Specific strategies directed 
against these few cells could kill specifically the repopulating nucleus of 
the tumor and eradicate the malignancy. (from Post Chemotherapy Stem 
Cells Treatment For Cancer, March 2013.) 
 
1.1.4. Asymmetric cell divisions and cancer  
Asymmetric divisions are a key mechanism to ensure tissue homeostasis. In 
normal stem cells they are controlled by intrinsic and extrinsic mechanisms. 
Intrinsic mechanisms involve partitioning of cell components that determine 
cell fate, such as cell polarity factors or cell fate determinants. A classic 
example comes from the C. elegans zygote asymmetric localization of the 
PAR-3, PAR-6 and atypical protein kinase C (PAR–aPKC) complex at the 
cortex. The asymmetrically localized PAR proteins in turn govern both mitotic 
spindle orientation and asymmetric segregation of cytoplasmic cell fate 
determinants. In Drosophila neuroblasts a related mechanism involves the 
evolutionarily conserved cell fate determinant, NUMB, which is 
asymmetrically localized to daughter cells that are committed to differentiate 
by antagonizing the Notch signaling (Bultje et al. 2009). Extrinsic mechanisms 
involve the asymmetric placement of daughter cells relative to external stimuli. 
In this mechanism of regulation has great importance the stem cell niche, 
defined as a 'microenvironment' that promotes stem-cell maintenance. In 
Drosophila, for example, germline stem cell divides with a reproducible 
orientation to generate one daughter that remains in the stem-cell niche and 
retains stem-cell identity, and one daughter that is placed away from the niche 
and begins to differentiate (Doe and Bowerman 2001). Symmetric stem-cell 
divisions have been observed during the development of both invertebrates and 
vertebrates but it has been found still present in the adult C. elegans germ line. 
Also in mammals, some adult stem cells seem to divide asymmetrically under 
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steady-state conditions, but they retain the ability to divide symmetrically to 
restore stem-cell pools depleted by injury or disease. In normal stem and 
progenitor cells, asymmetric divisions balance proliferation and self-renewal 
with cell-cycle exit and differentiation (Morrison and Kimble 2006). An 
interesting model of how adult stem cells can divide both symmetrically and 
asymmetrically comes from epithelia (Fig. 1.3). The capacity for symmetric 
stem-cell self-renewal may confer developmental plasticity and enhanced 
regenerative capacity, but has also implications with cancer (Fig. 1.3F). The 
first suggestion that the loss of asymmetric divisions might be involved in 
tumorigenesis came from Drosophila neuroblasts. Studies of loss-of-function 
mutations in key regulators of asymmetric divisions revealed 
hyperproliferative phenotypes in situ. In these mutants, presumably due to 
defective asymmetric divisions, cells divide more symmetrically and generate 
progeny that fails to exit the cell cycle and differentiate, but rather proliferates 
continuously. Molecular mechanisms underline defects in polarity and 
asymmetric divisions in human cancer initiation and progression remain poorly 
understood, but it is now clear that the asymmetric division acts as tumor 
suppressor mechanism by impairing aberrant self-renewal, invasion and 
matastasis, promoting differentiation and regulating cell polarity (Morrison and 
Kimble 2006). 
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Figure 1.3. Schematic overview of symmetric/asymmetric divisions in 
epithelia. A. Division in the plane of the epithelium generates two 
morphologically similar daughter cells that are both likely to be stem cells 
(orange). Grey line, basement membrane. B. Division perpendicular to the 
plane of the epithelium generates one stem cell and one differentiated 
daughter (green). C. During development, symmetric divisions expand the 
stem-cell pool. D. In healthy adults, divisions perpendicular to the 
epithelial plane typically maintain normal numbers of stem cells and 
differentiated cells in the basal layer of epithelia. E. In healthy adults, cells 
can be lost to injury (X). Symmetric divisions are proposed to regenerate 
additional stem cells, and asymmetric divisions to regenerate 
differentiated daughters. F. Defects in the balance between symmetric and 
asymmetric divisions can lead to tumorigenesis (left). A defect favouring 
asymmetric divisions results in decreased capacity for tissue repair (right). 
(From Morrison and Kimble, Nature reviews, 2006. ) 
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1.1.5. SCs regulatory networks  
Polarity is a fundamental property of eukaryotic cells and cell-fate 
determination is necessary in a range of contexts. It is often specified by 
asymmetric cell division, in which molecular pathways exert an important 
regulatory function and fate determinants become differentially distributed 
between daughter cells. SC self-renewal and differentiation is tightly controlled 
by multiple regulatory networks, including cytokines from the cancer cell 
microenvironment, also refferred as stem cell niche. Many signaling pathways 
including Wnt/β-catenin, Notch, Hedgehog and microRNAs, have a close 
relationship with the cell polarity and the regulation of the 
symmetric/asymmetric division ratio. 
 
1.1.5.1. Wnt/β-catenin 
The canonical Wnt cascade has emerged as a critical regulator of stem cells. In 
many tissues, activation of Wnt signalling has also been associated with cancer 
and later found tightly associated with self-renewal in stem and progenitor cells 
and subverted in cancer cells to allow malignant proliferation (Blank et al. 
2008). 
Wnt signaling is initiated when a ligand binds to the Frizzled and lipoprotein 
receptor-related protein (LRP) receptors at the cell surface. In the absence of 
Wnt ligands, the downstream signal transducer β-catenin is trapped by 
adenomatous polyposis coli (APC) and Axin in a destruction complex, where it 
is phosphorylated by casein-kinase 1α (CK1α) and glycogen synthase kinase 
(GSK3β). Phosphorylation ultimately leads to ubiquitination and degradation 
of β-catenin. On ligand binding, Frizzled forms a complex with Disheveled 
(Dsh), whereas LRP is phosphorylated, resulting in Axin relocation to the cell 
membrane. Subsequently, the destruction complex is dispersed and β-catenin 
accumulates and translocates to the nucleus where it interacts with the T-cell 
factor/lymphoid enhancer factor (TCF) transcription factors to regulate gene 
expression (Blank et al. 2008). 
Increased Wnt signaling gives rise to pituitary tumors in mice (Gaston-Massuet 
et al. 2011) and Wnt drives symmetrical cell divisions in stem cells (Le Grand 
et al. 2009). 
 
1.1.5.2. Notch 
Notch receptors are single pass transmembrane proteins. The receptor is 
processed in the ER and Golgi resulting in cleavage, producing a glycosylated 
Ca2+ stabilized heterodimer. The processed receptor is translocated to the 
membrane where it binds ligands, members to the Delta-like and Jagged 
family, located in the signal-sending cells. When ligands of the Delta (Delta1-
3) or Jagged (Jagged 1-2) families bind to the Notch receptor, proteolytic 
events involving γ-secretase lead to release and translocation of the 
intracellular domain of the receptor (NICD) to the nucleus. Subsequently, 
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NICD will form a complex with the transcription factor CSL and cofactors of 
the Mastermind-like (MAML) family to activate transcription of target genes 
(Chiba 2006).   
The role of Notch as cell fate determinant has been extensively studied in 
particular in neural development. Indeed, Notch signaling can promote glial 
determination, in addition to inhibiting the determination of neurons. Its  
activity often specifies the most undifferentiated state during cell fate decisions 
and is thought to help in maintaining the multipotent character of stem cells as 
they divide. Notch activation contributes to the expansion of a variety of stem 
and early progenitor cells (Chiba 2006). The activation of the Notch signaling 
pathway have been demonstrated to increase the self-renewal capacity of long-
term in vivo repopulating HSCs (Stier et al. 2002; Kunisato et al. 2003) or even 
to immortalize primitive hematopoietic progenitor cells (Varnum-Finney et al. 
2000). Given its role in the regulation of stem cells expansion by counteracting 
the asymmetric cell division, the de-regulation of Notch activation is tightly 
correlated with cancer development (Moeini et al. 2012). 
 
1.1.5.3. Hedgehog 
Hedgehog (Hh) is involved in a signaling cascade that regulates development 
and expansion of tissue progenitor or stem cells. The Hh ligand is translated as 
a precursor, which undergoes autocatalytic processing to form an N-terminal 
fragment. Secretion and paracrine signaling requires participation of the 
Dispatched proteins. The family comprises Indian hedgehog, desert hedgehog 
and Sonic hedgehog. These proteins bind the patched receptor (PTCH1), 
depressing its constitutive repression of Smoothened (Smo), leading to 
activation of the Gli transcription factors (Yu  et  al.  2012). Hh signaling is 
crucial for self-renewal of neural SCs, and its deregulation is often associated 
with the tumorigenic progression of neural SCs. Not surprisingly, the 
subversion of the Hh pathway has been implicated in a variety of 
developmental abnormalities, and in different types of cancers (Teglund and 
Toftgard 2010). 
 
1.1.5.4. p53 
The tumor suppressor protein p53 functions mainly as a transcription factor, 
inducing the expression of genes involved in cell-cycle arrest, senescence and 
apoptosis in response to cellular stress. In unstressed cells, therefore, p53 is 
kept inactive, mainly through proteasomal degradation induced by the E3 
ubiquitin ligase MDM2 polyubiquitination. Loss of MDM2 binding or 
inhibition of its E3 ligase activity allows p53 to be rapidly stabilized and 
activated in response to a variety of cellular stresses that are associated with 
tumor development and progression, including DNA damage, oncogene 
activation, hypoxia and metabolic stress. The tumor suppressor activity of p53 
is affected in most, if not all, cancers. This is frequently achieved by mutations 
in p53 (Hainaut and Hollstein 2000) or, less commonly, by amplification of the 
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gene for MDM2 (Momand et al. 1998). In some tumors other machanisms can 
act to prevent the activation of the p53 pathway. 
Recently, interesting findings highlighted an important role of p53 in 
regulating the symmetric/asymmetric division ratio in CSCs. Indeed, using the 
ErbB2 transgenic model of breast cancer, first, it was found that CSCs are 
characterized by more frequent self-renewing divisions compared to their 
normal counterparts, thus contributing to increasing numbers of SCs in tumoral 
tissues. Further, primary SCs with mutation in p53 revealed the same self-
renewal properties of CSCs, and their number increases progressively in the 
p53 null premalignant mammary gland. After pharmacological reactivation by 
using Nutlin-3, which acts by displacing  p53 from its E3-ligase mdm2, the 
asymmetric divisions in CSCs was restored and tumor growth reduced 
(Cicalese et al. 2009). 
In mouse embryonic stem cells (ESCs) p53 is highly abundant, it was found to 
be inactive and localized mainly in the cytoplasm (Han et al. 2008). Several 
studies have highlighted the importance of p53 in regulating suppression of 
self-renewal and induction of differentiation after DNA damage. Indeed, 
master transcription factor Nanog and the pluripotency factor Oct4 are known 
to drive self-renewal and the maintenance of an undifferentiated state in mouse 
ESCs (Mitsui et al. 2003). In DNA damaged ESCs mouse, p53 binds and 
suppress their promoters, thus forcing differentiation into cell types that can be 
subjected to classical p53 processes such as cell-cycle arrest or apoptosis. 
Moreover, p53 was found to activate the expression of miR-34a and miR-145, 
which in turn repress stem cell factors Oct4, KLF4, LIN28A and Sox2 and 
prevent backsliding to pluripotency (Jain et al. 2012). It was also found that the 
compromization of p53 enhance the iPSC generation. Furthermore, it was 
suggested that p53 may induce cell cycle arrest and apoptosis and thus function 
as a barrier to select exclusively perfect reprogrammed SCs. In mesenchymal 
stem cells (MSCs) mutations in oncogenes or tumor suppressors may function 
as tumor initiating cells (TICs) leading to tumor formation. Transformation of 
MSCs seems to be highly dependent on alterations in the p21/p53 pathway, 
mainly by the abolishment of WT p53, but not on the retinoblastoma. 
Heterozygous p53 SCs are at the junction between normal SCs and CSCs, 
which concomitantly express a functional WT p53 and a mutant p53. The 
tumor transformation follows the loss of the WT p53 generally due to loss of 
heterozygosity (LOH), but in the 40% it is due to diverse mechanisms such as 
promoter hypermethylation, increased activity of Mdm2, the E3 ligase 
responsible for p53 ubiquitination and so on (Aloni-Grinstein et al. 2014). All 
these findings support the idea that p53 has an important role as barrier to the 
cancer stem cells formation. 
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Figure 1.4. p53 as barrier to CSCs formation. p53 restricts processes of in 
vivo dedifferentiation and in vitro reprogramming, preventing the 
transformation and dedifferentiation of differentiated cells into CSCs. SCs 
have the potential to undergo mutation in p53. In heterozygous p53 SCs, 
LOH can occur as a DNA repair process, leading to the loss of the mutant 
allele and ensuring the quality of the SCs. In the case where the WT allele 
is lost, CSCs will be formed. (from Aloni-Grinstein et al., FEBS letters,  2014) 
 
1.1.5.5. Numb 
Numb is an important cell fate determinant which acts at different levels in the 
development and in the stem cell division. Mice lacking Numb exhibit 
profound defects in angiogenic remodelling and neural-tube closure, and lack 
several neuronal cell lineages (Zhong et al. 2000) (Zilian et al. 2001). An 
asymmetric distribution of Numb has been reported in mitotic neural 
progenitors in the mouse forebrain (Zhong et al. 1996). In mammalian 
epithelial cells, endogenous Numb is localized primarily to the basolateral 
cortex (Dho et al. 2006), indicating that Numb also maintains a polarized 
distribution in non-mitotic cells. During mitosis, the cell-fate is modulated by 
the Baz/Par6/aPKC complex that directs the basal distribution of the cell-fate 
determinant NUMB; after aPKC phosphorylation, Numb is released from the 
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apical cortex and localizes to the basal side of the cell. (Gomez-Lopez et al. 
2014) 
Numb regulates endocytosis by participating to cargo internalization and 
recycling. Further, by interacting with PAR complex it has an important role in 
determining cell polarity, since the asymmetrical localization of PAR proteins 
governs both mitotic spindle orientation and asymmetric segregation of 
cytoplasmic cell fate determinants. Numb is also connected with signaling 
molecules, by regulating Notch and Hedgehog activated pathways (Pece et al. 
2011). Particular importance it has been attributed to its role in antagonizing 
Notch. Numb’s interaction with endocytic proteins has led to the hypothesis 
that it may regulate Notch by promoting removal of the Notch receptor from 
the plasma membrane into endosomes. Indeed, the Notch receptor trafficking 
through the endocytic pathway is important for Notch signaling 
regulation(Fortini and Bilder 2009). This hypotesis has been replaced with 
another more complex mechanism by which Numb regulates Notch through 
Sanpodo, which is expressed only in asymmetrically dividing cells by 
associating with Numb and Notch, thus regulating Notch signaling only during 
asymmetric divisions (Hutterer and Knoblich 2005). Notch and Sanpodo act 
together in opposition to Numb in cell fate determination (Skeath and Doe 
1998), Numb inhibits the membrane localization of Sanpodo and toghether 
with α-adaptin controls the endocytosis of Sanpodo. Besides this mechanisms, 
in mammalian cells, Numb is able to bind the E3 ubiquitin-ligase, Itch, and to 
cause the ubiquitination of Notch (Qiu et al. 2000). 
In stem cells, Numb activity is regulated by asymmetric partitioning at mitosis, 
leading to unequal distribution of Numb in daughter cells that are then destined 
for different fates. In particular the daughter cell which inherits Numb will be 
committed to differentiate. This particular feature together with its role in 
regulating cell fate, self-renewal and differentiation, leads to correlate Numb 
with tumor development. Also, it has been found that the loss of NUMB occurs 
frequently in breast tumors, leading to activation of oncogenic Notch signaling 
(Pece et al. 2004) and to the inactivation of the p53 tumor suppressor pathway, 
as more recently demonstrated (Colaluca et al. 2008). Primary tumor cells with 
low or normal levels of NUMB, revealed that loss of NUMB correlates with 
reduced levels of p53 and also with resistance to chemotherapeutic agents, 
more aggressive neoplastic disease and poor prognosis. Toghether with these 
findings Colaluca et al. showed that NUMB is able to interact in vivo with 
endogenous MDM2 and p53, resulting in a trimeric complex between the three 
proteins. This interaction appears to regulate the stability of p53, and 
consequently the levels of the protein (Colaluca et al. 2008). Since, as 
described above, also p53 has a fundamental role in regulating asymmetric cell 
division, the tight connection between p53 and NUMB confirm their 
importance in the prevention of CSCs formation. 
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1.1.5.6. microRNAs in CSCs 
In recent years it has emerged that miRNAs are implicated in the regulation of 
a broad range of biological processes including embryonic development, cell 
cycle, cell proliferation, tumor initiation and progression, cancer metastasis, 
self-renewal, and differentiation of stem cells (Yu et al. 2007). The first two 
miRNAs found in the stem cells regulation were lin-4 and let-7, involved in 
regulating the timing of larval to adult cell fates in C. elegans (Lee et al. 1993). 
miRNA play important functional roles in the establishment and maintenance 
of a core network of transcription factors and RNA binding proteins.  
Transcriptional factors important for the ES identity such as OCT4, Sox2, 
Nanog, Klf4, c-Myc, Tcf3, Lin28 are regulated by the miR-290, 302, 371; 
further they also regulates Lin28 and c-Myc. Anti-stemness miRNAs includes 
miR-134, miR296, miR-200c, miR-203, miR-183 and let-7 miRNAs.  let-7 
over-expression inhibits mammosphere formation, and metastasis of breast 
CSC (Yu et al. 2007), whereas reduced let-7 expression maintains the 
undifferentiated state of breast CSCs. let-7 may also regulate self-renewal by 
targeting H-RAS and the differentiation via HMGA2 in breast CSC. Recently it 
has been found able to regulate self-renewal in colon CSCs. miR-34a loss of 
function and gain of function alter the balance between self-renewal versus 
differentiation both in vitro and in vivo. Indeed it is able to regulate Notch by 
sequestering Notch mRNA. This activity, togheter with the modulation of 
multiple targets besides Notch  determines cell-fate asymmetry in a robust and 
precise way during CSCs division (Bu et al. 2013). 
Further, there is an important interplay between miRNAs and the stem cell 
niche, since they can regulate immune cells, cancer associated fibroblasts, 
cytokines and chemokine in the tumor microenvironment. For instance, miR-
17/20 inhibits IL-8 secretion to block tumor stem cell migration and metastasis 
(Yu et al. 2012). 
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1.2. High Mobility Group A Proteins 
 
Life depends on the ability of a biological system to store, retrieve, process and 
translate the genetic instructions required to make and maintain a living 
organism. The packaging of all the information into chromosomes is achieved 
thanks to a series of molecules which both contribute in maintaining this 
ordered structure and regulate the accessibility to regulatory factors. Many 
studies have focused on histone proteins, but it is now clear that besides 
histones there is a second class of proteins, which are either part of, or 
associated with, the chromatin fiber. These proteins are referred to as non-
histone chromosomal proteins. 
The high mobility group (HMG) proteins are the largest and best characterized 
group of non-histone chromosomal proteins. They are defined as nuclear 
proteins with a high electrophoretic mobility in poly-acrylamide gels and 
typically, they have a high content of charged amino acids and a molecular 
mass <30 kDa (Cleynen and Van de Ven 2008).  
In 1983, two new high-mobility group-like proteins were found in HeLa cells 
and named Y and I. Goodwin and co-workers (Goodwin et al. 1973)identified 
two proteins in the nuclei of rat thymus and of fibroblasts transformed with 
avian sarcoma virus. These proteins were named Y and I′ because of their 
resemblance to the two proteins previously found by Lund et al. In the same 
period, A. Varshavsky's group studied the binding to the DNA of a mammalian 
protein called α subsequently found to be an HMG protein.  Later, these small 
DNA-binding proteins were categorized and named HMGA proteins (Lund et 
al. 1983). 
 
1.2.1. HMGA genes and protein structure  
HMGA family comprises three members named HMGA1a, HMGA1b, and 
HMGA2. 
HMGA1 gene is located on human chromosome 6 (6p21) and on mouse 
chromosome 17. The human HMGA1 gene is constituted of eight exons, 
distributed over a region of about 10 kb whereas the mouse hmga1 orthologue 
contains six exons spanning about 7 kb (Pedulla et al. 2001) (Johnson et al. 
1993). The human HMGA2 gene is located at chromosomal band 12q14-15 and 
contains five exons dispersed over a genomic region of ≥160 kb. The mouse 
hmga2 gene locates on chromosome 10 and contains five exons spanning more 
than 110 kb. Both human and mouse HMGA2/hmga2 genes are much larger 
than their HMGA1/hmga1 counterparts, mainly because of longer 5' and 3' 
untranslated regions and because of the extremely long third intron of 
HMGA2/hmga2 (Zhou et al. 1995). 
The HMGA1 gene undergoes alternative splicing, resulting in the generation of 
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three different mRNAs encoding HMGA1a (107 amino acids, 11.7 kDa), 
HMGA1b (96 amino acids, 10.6 kDa) and the more recently identified 
HMGA1c (179 amino acids, 19.7 kDa). The HMGA1a and HMGA1b isoforms 
differ by only 11 internal amino acids present in HMGA1a but not in 
HMGA1b and are encoded by the most abundant splice variants of the HMGA1 
gene. HMGA1c is produced from the HMGA1 gene by alternative splicing 
using non-canonical splice donor and acceptor sites. This alternative splicing 
results in a frameshift so that the two proteins are identical in their first 65 
amino acids but differ thereafter.  
HMGA1a, HMGA1b and HMGA2 are polypeptides of about one hundred 
amino acid residues characterized by a modular sequence organization. These 
proteins presents highly conserved regions, rich in positively charged regions, 
called AT-hooks, since they bind A-T rich regions in the minor groove of B-
form DNA; their feature is to recognize structure, rather than a particular 
nucleotide sequence. The AT-hook motif is a positively charged stretch of 9 
amino acids containing the invariant repeat Arg-Gly-Arg-Pro (R-G-R-P), 
flanked by other positively charged residues, usually Arg (R) and Lys (K). Free 
in solution, A T -hooks possess little, if any secondary structure. Upon binding 
to DNA, the AT-hook undergoes a disordered-to-ordered conformational 
change. Depending on the number and spacing of AT-rich binding sites in 
DNA, HMGA proteins can influence the conformation of bound DNA 
substrates in different ways. 
The C-terminus domain has completely different features since it contains a 
high percentage of negatively charged acidic residues. Among different 
HMGA proteins, the three AT-hooks are differently spaced along the protein 
molecules, resulting in an interactive modular system constituted by a set of 
three proteins able to establish interactions with differently spaced AT-rich 
DNA regions. The HMGA proteins show an unusual capability to bind other 
nuclear proteins; indeed, they are able to bind to a great number of partners, by 
which they are involved in regulating and in performing a myriad of functions 
(Sgarra et al. 2004) (Cleynen and Van de Ven 2008). 
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Figure 1.5. Structure of human HMGA1/HMGA2 genes and proteins.  
HMGA1(A) and HMGA2 (B) proteins have a similar structure and are well 
conserved during evolution. In this picture AT-hooks are represented in 
green, in red the C-terminus domains of the proteins. (from Fusco and 
Fedele, Nature Reviews, 2007) 
 
1.2.2. HMGA mechanisms of action  
As mentioned above, HMGA proteins do not exhibit transcriptional activity 
per se, but they regulate the activity of several genes by interacting with the 
transcription machinery and altering the chromatin structure (Reeves and 
Beckerbauer 2001). The levels of HMGA proteins are low or absent in normal 
cells and adult tissues but are elevated in many tumors, neoplastically 
transformed cells, and embryonic cells (Fedele and Fusco 2010). HMGA 
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proteins participate in a wide variety of nuclear and cytoplasmatic processes, 
ranging from chromosome and chromatin dynamics, such as chromosome 
condensation, to architecture-mediated transcriptional regulation. 
 
1.2.2.1. Transcriptional regulation 
HMGA proteins seem to function as an anti-repressor of transcription since 
they are able to induce the remodeling of the inhibitory chromatin complexes. 
Thus they control the global structure of large loops or domains of chromatin. 
In one important machanism, HMGA proteins bind to the SARs at the base of 
repressed chromatin loops and concomitant displacement/exclusion of histone 
H1 from these sequences leads to a local opening of chromatin and initiation of 
the gene activation process. Further, HMGA proteins are proposed to be 
involved in the initial remodelling of the inhibitory nucleosomes and the 
subsequent formation of an enhanceosome (Cleynen and Van de Ven 2008). 
 
1.2.2.2. Long-range chromatin interactions 
The HMGA proteins have been proposed to be involved in long-range 
enhancer-promoter interactions. For example, inducible expression of the 
chicken ß-globin gene requires a functional interaction between a specialized 
TATA-box motif located at -30 bp in the gene 5' promoter and a distal 3' 
enhancer element located ±1.9 kb downstream of the start of the ß-globin 
coding region (Fong and Emerson 1992). Bagga et al demonstrated that 
HMGA1 proteins mediate chromatin looping and long-range interactions of 
these widely spread regulatory regions to regulate the chicken ß-globin gene 
(Bagga et al. 2000) 
 
1.2.2.3. Protein-protein interactions 
HMGA proteins can also influence gene transcription, without first binding to 
DNA, via direct protein-protein interactions with transcriptional factors. 
HMGA proteins, indeed, are able to bind to many transcriptional factors. After 
the binding, HMGA proteins induce conformational changes in the substrate. 
These interaction sites are distributed along their entire length. Generally the 
site of interaction includes part, or the whole, of one or more AT -hook motifs, 
plus flanking regions. The region between the second and third AT-hook of the 
HMGA1 protein, for example, has the most of identified interacting partners 
(Reeves and Beckerbauer 2001). 
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1.2.2.4. Viral integration 
It has been demonstrated an involvement of HMGA proteins during infectious 
processes; they act, for example, as co-factors during the infection of HIV-1. It 
has been proposed a mechanism by which HMGA proteins both bind multiple 
AT-rich sites on retroviral cDNAs in pre-integration complexes, favouring  the 
viral integration, and act on AT -rich regions of viral promoter/enhancer 
regions, cooperating with both viral copies and host proteins in the control of 
viral gene transcription (Li et al. 2000). 
 
1.2.3. Physiological functions of HMGA proteins  
1.2.3.1. Growth and differentiation 
In normal conditions the expression of HMGA proteins is restricted to 
embryogenesis, until 8.5 dpc, it decreases with organogenesis and in normal 
adult cells is very low or almost absent. HMGA1 expression is confined to 
specific organs of ectodermal, mesodermal and endodermal origin, while 
HMGA2 expression is restricted to mesenchimal tissues. A role for both 
factors in development has been demonstrated. Indeed, genetic studies in mice 
have isolated four viable, spontaneous mutants showing dwarfism (Zhou, 
Benson et al. 1995). Three of the four phenotypes could be explained by 
aberrations in the growth hormone insulin-like growth factor endocrine 
pathway. One of the phenotypes, called ‘pygmy’results from the disruption of 
the hmga2 gene. 
Further, it has been found that HMGA2 is correlated to adipogenesys, since the 
deficiency of the Hmga2 gene in mice results in resistance to obesity induced 
by diet (Anand and Chada 2000) .The phenotype of HMGA1 knockout mice 
has not been reported possibly because the more general expression of this 
factor could severely impair development. Indeed, suppression of HMGA1 
expression impairs differentiation of pre-adipocytic cells, 
lymphohematopoietic differentiation and normal sperm development (Sgarra et 
al. 2004). To better clarify the role of hmga1 proteins in embryonic 
development, Battista et al used ES cells carrying disruption of one or both 
alleles of the hmga1 gene. It appeared that hmga1 proteins are involved in 
different hematopoietic lineage commitment checkpoints. In hmga1-/- 
embryoid bodies (EBs), myeloid differentiation was shown to be impaired, 
while megakaryocytic and erythroid differentiation was shown to be increased 
(Battista et al. 2003). An important role of hmga1 in mice developmemente 
was highlighted also by Fedele et al. Heterozygous and homozygous mice for 
the hmga1-/- allele showed cardiac hypertrophy due to the direct role of 
HMGA1 on cardiomyocytic cell growth regulation. These mice also developed 
hematologic malignancies, including B cell lymphoma and myeloid 
granuloerythroblastic leukemia (Fedele et al. 2006). 
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1.2.3.2. Senescence 
Recently it has been proposed a new role for HMGA proteins in promoting 
senescence. Cellular senescence is a stable state of proliferative arrest that 
provides a barrier to malignant transformation and contributes to the antitumor 
activity of certain chemotherapies. Senescent cells can accumulate senescence-
associated heterochromatic foci (SAHFs), which may provide a chromatin 
buffer that prevents activation of proliferation-associated genes by mitogenic 
transcription factors. It was found that HMGA proteins cooperate with the 
p16INK4a tumor suppressor to promote SAHF formation and proliferative arrest 
and stabilize senescence by contributing to the repression of proliferation-
associated genes. This function can be accomplished only in the absence of two 
factors, HDM2 and CDK4, which are generally amplifyed during 
tumorigenesis (Narita et al. 2006).  
 
1.2.3.3. DNA repair 
HMGA proteins are involved in the regulation of the DNA repair mechanisms 
in at least two ways. First, it has been demonstrated that HMGA1 is involved 
in the nucleotide excision repair. HMGA1 can hamper nucleotide excision 
repair both by physically inhibiting access of DNA repair-associated proteins 
to cyclobutane pyrimidine dimer (CPD) lesions, by directly binding to the UV-
induced lesions (Adair et al. 2005), (Maloney et al. 2007) and by physical 
interacting with repair factors, thereby inhibiting their function. 
Second, HMGA1 and HMGA2, interact and are phosphorylated by ATM in 
response to DNA damage. Interestingly, RT-PCR and Western Blot analysis on 
Mouse Emrbyonic Fibroblasts (MEFs) lacking HMGA1, HMGA2 or both 
genes, revealed that, in the absence of HMGA proteins, mRNA and protein 
levels of ATM are strongly reduced. Moreover, p53 phosphorylation and the 
consequent activation of p21 transcription, induced by ATM kinase activity, 
were significantly affected by the absence of HMGA proteins (Pentimalli et al. 
2008). 
 
1.2.3.4. Cell cycle regulation 
Many studies have highlighted a role for HMGA proteins in regulating cell 
cycle. As previously described, they are susceptible to phosphorylation 
mediated by important kinases involved in the control of cell cycle check 
points, such as Cdc2 kinase, thus modulating the affinity of HMGA proteins 
and enhancing their activity (Reeves and Nissen 1995). In 2001 it has been 
found that the overexpression of HMGA1b protein in rat thyroid cells is able to 
deregulate their cell cycle; indeed cells enter S-phase earlier and the G2-M 
transition is delayed (Fedele et al. 2001). Further, a role for HMGA proteins 
has been proposed in the alteration of the cell cycle as a critical event in 
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pituitary adenomas. HMGA2 overexpression is responsible of the upregulation 
of cyclin B2 gene transcription, leading to overexpression of cyclin B2 in 
pituitary adenomas developed by mice carrying hmga transgenes. Since cyclin 
B2, complexed with CDK1, plays a critical role in regulating the G2/M phase 
transition of the cell cycle, it is reasonable to hypothesize that cyclin B2 
induction by HMGA proteins may contribute to increase cell proliferation of 
the pituitary cells (Fedele and Fusco 2010). The role of HMGA proteins in 
neoplastic transformation will be further discussed in the following sections. 
 
1.2.3.5. Apoptosis 
The role of HMGA proteins in the regulation of apoptosis is controversial. It 
seems that in wild type, not transformed cellular systems, HMGA proteins 
function promoting the programmed cell death upon mitogenic stimuli. Indeed, 
it was shown that normal rat thyroid PC Cl 3 cells overexpressing HMGA1, 
which pushes cells through the S-phase, undergo apoptosis through a pathway 
involving caspase-3 activation, probably consequent to the conflict between 
mitogenic pressure and the inability to proceed through the cell cycle. It was 
also found that the third AT-hook domain and the acetylation site K60 are the 
protein regions required for induction of apoptosis in PC Cl 3 cells (Fedele et 
al. 2001). 
Further, our group have highlighted a role of HMGA proteins as anti-apoptotic 
factors in transformed systems. They act mainly on the p53 apoptotic pathway. 
In response to DNA damage, p53 induces either cell-cycle arrest or apoptosis. 
HMGA proteins act by inhibiting this pathway both by regulating at the 
transcriptional level the E3 ligase specific of mdm2/HDM2, thus promoting the 
p53 proteasome degradation and by direct interaction with the p53 protein. 
Also, recent studies have shown that in pancreatic carcinoma cell lines 
HMGA1 overexpression inhibits the phosphorylation of Akt, thus avoiding the 
activation of caspases 3, 8 and 9 upon exposure to chemotherapeutic agents 
These mechanisms by which HMGA proteins negatively regulate the apoptotic 
pathway in cancer cells will be further discussed below. 
 
1.2.4. Regulation of HMGA proteins  
HMGA genes expression can be regulated in response to a large array of 
cellular stimuli. Many growth factors are able to induce HMGA gene 
expression. Moreover, HMGA expression can be repressed by activation of a 
differentiation program. For example, in neuroblastoma and in embryonic 
carcinoma cells, HMGA1/2 expression can be repressed by retinoic acid. As 
mentioned above, the deregulation of the HMGA proteins expression is 
frequently associated to neoplastic transformation. 
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1.2.4.1. Transcriptional regulation of the HMGA1 gene 
Many studies focused on the role of HMGA1 in the regulation of cellular 
functions, but little is known about transcriptional regulation of HMGA1 gene. 
This is due to the extremely complex structure and transcriptional regulation of 
both the mouse and human HMGA1 gene. It comprises four different 
transcription start sites, of which the first two are considered to be the major 
ones (Ogram and Reeves 1995). A few cis-elements were carachterized on the 
HMGA1 promoter. Among these, a multiple cis-acting elements located near 
the first three transcription start sites  seems to be important for the HMGA1 
trans-activation performed by MYCN in neuroblastoma. Also studies in 
Burkitt's lymphoma reported that the oncogene c-myc is able to activate the 
HMGA1 gene expression. Further, it has been shown that the HMGA1 
promoter is strongly inducible by the oncogenic Ras, via a distal regulatory 
region (Cleynen and Van de Ven 2008). More recently it has been 
demonstrated that HMGA1 is a downstream target of the Wnt/β-catenin/TCF-4 
signalling pathway. Indeed, the deregulation of this pathway in colon 
carcinoma is associated with high levels of the HMGA1 expression, whereas 
the restoration of the Wnt pathway resulted in HMGA1 down-regulation. In the 
same study were highlighted two regions in the 5'-flanking sequence of 
HMGA1 that specifically bind the β-catenin/TCF-4 complex in vitro and in 
vivo (Bush et al. 2013). 
 
1.2.4.2. Transcriptional and post-transcriptional regulation of the HMGA2 
gene 
HMGA2 promoter also contains multiple transcription initiation sites, which 
are differentially used. In addition, they show that HMGA2 5'-flanking 
sequences had constitutive promoter activity in cell lines which express high 
levels of HMGA2, and in cell lines which do not express HMGA2. Thus 
probably, HMGA2 gene undergoes a negative regulation by cis-elements 
and/or a post-transcriptional regulation. In particular, the post-transcriptional 
regulation seems to be fundamental, since some rearrangements involving the 
3' UTR but leaving the ORF intact, lead to an HMGA2 overexpression 
(Schoenmakers et al. 1995) (Geurts et al. 1997), probably due to the loss of 
repressive elements in its 3' UTR. Within the last few years, miRNAs have 
emerged as important regulators of both transcriptional and post-transcriptional 
gene silencing. HMGA2 overexpression has been found correlated with the 
down-regulation of miR-15 and miR-16 (Palmieri et al. 2012). Recently, it was 
found that the HMGA2 transcript can be negatively regulated by let-7 miRNA 
(Fig. 1.6). As previously discussed, through the regulation of HMGA2, let-7 is 
able to modulate the self-renewal and asymmetric cell divisions in stem cells. 
The let-7 inhibition enhances cell proliferation in H1299 (Lee and Dutta 2007) 
cells and causes transformation in NIH-3T3 cells (Mayr et al. 2007; Cleynen 
and Van de Ven 2008).   
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Fig 1.6. The let-7 mechanism. A. The let-7 microRNA binds to the 3' region 
of the HMGA2 gene and thus downregulates HMGA2 expression by 
inhibiting translation and/or causing the degradation of the mRNA. B. 
Following truncation or fusion with ectopic sequences, HMGA2 loses the 
sites previously recognized by let-7, resulting in increased HMGA2 mRNA 
levels. Here, HMGA2 is in blue and its fusion partner is in red (Fusco, 
Fedele, Nature reviews, 2007). 
 
1.2.4.3. Post translational modifications 
All the mechanisms of action proposed above are influenced by post 
translational modifications. Indeed, HMGA proteins are among the most highly 
adducted proteins in the nucleus, exhibiting complex patterns of 
phosphorylations, acetylations, methylations and less frequently also 
sumoylation and ribosylation (Fig. 1.6). It is clear that after modifications 
HMGA proteins bind with different affinity both DNA and proteins, thus 
influencing their biological activities. Among the post-translational 
modifications, the more frequent is the phosphorylation. Many effectors such 
as protein kinase C, cdc2 kinase and Casein Kinase 2 are able to phosphorilate 
HMGA proteins in different sites of their structure and in specific phases of the 
cell cycle. Further It has recently been demonstrated that HMGA1 proteins also 
undergo methylation. Examples include Arg24 within the first AT-hook of 
HMGA1a, which has been found methylated in tumor cell lines. This kind of 
methylation is involved in the apoptosis process. Recently HMGA1a has been 
identified as a target of the protein arginine methyltransferase PRMT6, which 
specifically methylates HMGA1a on Arg56 and Arg58 within the second A T -
hook domain (Sgarra et al. 2006). 
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Figure 1.7. HMGA modifications. A. Schematic overview of the effect of 
post-translational modifications on HMGA binding properties. B. 
Simplified diagram of some of the post-translational modifications of the 
HMGA1 protein. (from Cleynen and Van De Ven, review 2007) 
 
1.2.5. HMGA Proteins And Cancer  
HMGA1 and HMGA2 are hardly detectable in adult human tissues, as well as 
hmga1 and hmga2 in mouse tissues. HMGA expression is very high during 
embryogenesis, whereas it is undetectable or very low in differentiated adult 
tissues (Zhou et al. 1995; Chiappetta et al. 1996), being confined, at least for 
HMGA2, to the staminal compartment (Rommel et al. 1997) (Anand and 
Chada 2000) (Nishino et al. 2008). Studies of mice models have revealed a 
crucial role of HMGA proteins in adipogenesis, somatic growth (Battista et al. 
1999), cardiac cell growth control (Fedele et al. 2006), and glucose 
homeostasis (Foti et al. 2005) (Chiefari et al. 2009). However, there are some 
exceptions to the general repression of these genes in adult tissues. For 
example, there is a burst of synthesis of the HMGA1a protein during the 
immune response (Shannon et al. 1998). Beside these, their overexpression 
represents a constant feature of human malignancies, and correlates with a poor 
prognosis.  
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1.2.5.1. HMGA proteins in benign tumors 
HMGA dysregulation, as a result of specific chromosomal rearrangements, 
occurs in a broad variety of common benign mesenchymal tumors, making 
HMGA genes among the most commonly rearranged genes in human 
neoplasms. They include lipomas (Tallini et al. 1997), uterine leiomyomas 
(Medeiros et al. 2007), pulmonary chondroid hamartomas (Kazmierczak et al. 
1996), fibroadenomas of the breast (Staats et al. 1996), endometrial polyps 
(Dal Cin et al. 1998), pleomorphic adenomas of the salivary glands (Persson et 
al. 2009) and vulvar aggressive angiomyxoma (Nucci et al. 2001). As 
mentioned above, many rearrangements involving the HMGA2 gene lead to 
the gene overexpression, truncation or, more frequently, generation of fusion 
genes encoding chimeric transcripts. As a consequence, the rearranged 
HMGA2 gene codes for a chimeric or a truncated HMGA2 protein that 
maintains its capacity to bind DNA and interact with several proteins, but loses 
its C-terminal tail, including the 3′ UTR. Concerning HMGA1, chromosomal 
breakpoints of rearrangements are located either upstream or downstream of 
the gene sequence, but no intragenic rearrangements have been found. As 
mentioned above the involvement of HMGA gene mutations in mesenchymal 
tumors seems to be correlated to deletions of its 3′ UTR. The consequent 
HMGA overexpression is due to the loss of the negative regulation exerted by 
miRNAs, such as let-7, miRNA-98 and miR-16 (Mayr et al. 2007) (Hebert et 
al. 2007) (Kaddar et al. 2009), on the 3′ UTR sequences of the HMGA genes. 
Many studies focused on the role of HMGA proteins in pituitary adenomas. 
Indeed mice expressing an Hmga2 transgene either in its wild-type or truncated 
form,  developed pituitary adenomas that secrete prolactin and growth hormone 
by the age of 6 months (Fedele et al. 2002). The same phenotype was also 
shown by mice over- expressing Hmga1 (Fedele et al. 2005). Studies in nine 
human prolactinomas revealed an increased dosage of the HMGA2 locus and 
its overexpression in most of them, whereas no HMGA2 expression was 
detected in normal pituitary cells (Finelli et al. 2002). Interesting and recent 
findings showed that a possible mechanism by which HMGA2 is 
overexpressed, involves the down-regulation of miR-15 and miR-16 that 
occurrs in human prolattinomas; HMGA proteins were demonstrated to be 
targets of these two miRNAs (Palmieri et al. 2012).  
Studies conducted on HMGA2-trangenic mice allowed to clarify a critical role 
of E2F1 activation in pituitary adenoma. In fact, mice obtained by crossing 
Hmga2-transgenic with E2F1 knockout mice showed a milder pituitary 
phenotype compared to the Hmga2 transgenic mice in a wild-type E2f1 genetic 
background (Fedele et al. 2006). It was also demonstrated that the E2F1 
activation is dependent on overexpression of HMGA2 that causes a 
displacement of HDAC proteins from the RB/E2F complex and, consequently 
leads to the acetylation and stabilization of the E2F-free factor (Fedele et al. 
2006). This model provides a very nice example of the mechanism of action of 
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HMGA proteins to activate transcription and of the effect of post-translational 
modifications on their function. 
 
   
  
Figure 1.8. E2F transcriptional regulation. The transcriptional activity of 
the E2F family of transcription factors is crucial for the expression of 
several genes required to enter the S-phase of the cell cycle. Hmga2 acts by 
displacing HDAC1 from E2F1 target promoters, hereby recruiting histone 
acetylases which first acetylate the histones - relieving transcriptional 
repression - and then also acetylate E2F1 causing its stabilization. (from 
Fusco, Fedele. Nature reviews, 2007). 
 
1.2.5.2. HMGA proteins in malignancies. 
The most studied and remarkable observation about HMGA proteins is that a 
generalized overexpression of HMGA1 and often HMGA2 characterizes 
neoplastic cells. Overexpression of members of the HMGA family, in 
particular of HMGA1, was first observed in HeLa cells (Lund et al. 1983) and 
in cultured rat thyroid transformed by the Kirsten murine sarcoma virus. The 
latter revealed the specific presence in KiMSV transformed cells of HMGA1a, 
HMGA1b and HMGA2 proteins (Giancotti et al. 1985). Further,  it was found 
that rat thyroid PC Cl 3 transformed by the v-ras oncogene, which does not 
confer to them the tumorigenic phenotype, did not express HMGA proteins, 
revealing that the presence of HMGA proteins is associated with an aggressive 
phenotype. The confirmation of the presence of HMGA proteins in thyroid 
carcinomas and metastases but not in normal thyroid tissue (Chiappetta et al. 
1995) prompted further studies to investigate of HMGA proteins expression in 
human thyroid neoplasms.  It was found that HMGA1 protein was detectable in 
121 of 126 thyroid carcinomas analyzed, in about 20% of benign adenomas, 
and essentially in no hyperplastic thyroid tissues. Moreover, a correlation 
between HMGA1 expression levels and aggressiveness of the tumors was 
observed, since the highest HMGA1 expression was detected in the anaplastic 
histotype, that represents one of the most aggressive and invariably lethal 
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cancers in the humans (Chiappetta et al. 1998). 
Overexpression of HMGA proteins has been described in different types of 
cancer. These include prostate (Tamimi et al. 1996) (Tamimi et al. 1993) 
colorectum (Kim et al. 1999) (Fedele et al. 1996) (Chiappetta et al. 2001), lung 
(Sarhadi et al. 2006), breast (Flohr et al. 2003) (Chiappetta et al. 2004), 
pancreas (Abe et al. 2000) (Abe et al. 2002). sarcomas (Berner et al. 1997), 
oral squamous cell carcinomas (Miyazawa et al. 2004), and non-small cell lung 
cancer (Meyer et al. 2007). In most of them, increasing levels of HMGA1 
proteins are correlated with increasing degrees of malignancy or metastatic 
potential. For example, in breast carcinoma it was found a correlation between 
HMGA1 and c-erbB-2, whose expression represents an indicator of a poor 
prognosis (Chiappetta et al. 2004). 
Many in vitro and in vivo studies over years supported the role of HMGA1 and 
HMGA2 overexpression in tumor development, also providing evidence of the 
causal involvement of HMGA proteins in cancer. Indeed, it has been found that 
the block of HMGA1 protein synthesis by an antisense methodology prevents 
rat thyroid malignant cell transformation induced by myeloproliferative 
sarcoma virus or Kirsten murine sarcoma virus, carrying oncogenes v-mos and 
v-ras-Ki, respectively, providing evidence that HMGA1 is required for thyroid 
cell tranformation (Berlingieri et al. 1995) (Berlingieri et al. 2002). Further, the 
HMGA1 silencing induces cell death in two human thyroid anaplastic 
carcinoma cell lines, but not in normal thyroid cells (Scala et al. 2000).  It was 
also demonstrated that increased expression of both HMGA1 and HMGA2 
proteins leads to neoplastic transformation of Rat1a fibroblasts with anchorage-
independent cell growth (Wood et al. 2000), whereas in lung and pancreatic 
carcinoma cell lines HMGA1 silencing reduced the anchorage-independent 
proliferation in soft agar and increased susceptibility to anoikis (Liau et al. 
2007). Moreover, in human pancreatic cancer cells the knockdown of HMGA2 
inhibited cell proliferation, leading to an epithelial-state transition that restores 
cell-cell contact due to E-cadherin up-regulation (Watanabe et al. 2009). 
Hmga1a, hmga1b and hmga2 transgenic mice were developed. Both hmga1b 
and hmga2 transgenic mice develop mixed growth hormone/ prolactin cell 
pituitary adenomas, abdominal/pelvic lipomatosis and/or an abnormally high 
incidence of lipomas and NK-T/NK cell lymphomas. A crucial step in the 
onset of pituitary adenomas in hmga2 transgenic mice, and probably also in 
humans, is E2F1 activation, as described above (Fedele et al. 2006). 
Further, transgenic mice that misexpressed full-length or truncated human 
HMGA2 transcript under the control of the promoter of the adipocyte P2 
(Fabp4) gene, specific of mesenchymal differentiated cells, produced 
neoplastic phenotype, including fibroadenomas of the breast and salivary gland 
adenomas (Zaidi et al. 2006). Hmga1a transgenic mice develop aggressive, 
highly penetrant lymphoid malignancy and HMGA1a is also overexpressed in 
human lymphoid leukemia (Pierantoni et al. 2003; Xu et al. 2004). In addition 
to lymphoid malignancy, Hmga1a transgenic mice develop uterine tumors, 
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which resemble human uterine adeno-sarcomas (Tesfaye et al. 2007). Further, 
hmga1 null mice are less susceptible to chemically induced skin carcinogenesis 
(Baldassarre et al. 2001). 
 
1.2.5.3. Mechanisms of HMGA proteins oncogenicity 
The role of HMGA proteins in cell transformation is essentially based on its 
ability to modulate the expression of genes critical for the tumorigenic process, 
involved in fundamental cellular functions, such as cell proliferation and 
invasion. 
 
1.2.5.3.1. Activation of the AP1 complex 
After discovering the importance of HMGA1 for the establishment of the 
neoplastic phenotype, our group also showed its ability to control the AP-1 
complex in retrovirally transformed thyroid cell lines. This complex is 
constituted of three Jun proteins (JUN, JUNB and JUND) and four Fos proteins 
(FOS, FOSB, FRA1 (also known as FOSL1) and FRA2 (also known as 
FOSL2) and it is responsible for the activation of various target genes involved 
in the control of cell proliferation, tumorigenesis and metastasis(Angel and 
Karin 1991; Karin et al. 1997) It was found that HMGA1 exerts a positive 
regulation activity on this complex, in particular on JUNB and FRA-1, which 
are strongly up-regulated in the neoplastic transformation induced by the 
HMGA1 overexpression. Conversely, the HMGA1 antisense is able to 
prevent JUNB and FRA-1 overexpression. These results indicated that 
HMGA1 is essential for the JUNB and FRA-1 transcriptional induction 
associated with neoplastic transformation. (Vallone et al. 1997). 
 
1.2.5.3.2. Cell cycle regulation 
HMGA proteins exert their control on the cell cycle both directly and 
indirectly. Indeed, as previously discussed, HMGA2 is able to activate E2F1 
by displacing histone deacetylase 1 from the pRB–E2F1 complex; it leads to an 
enhanced acetylation of both E2F1 and DNA-associated histones. Further, 
HMGA2 regulates the expression of several cyclins through E2F1, including 
cyclin A and other proteins required for the cell-cycle progression, both at the 
S-phase entry and at the G2/M transition  (Pagano et al. 1992). Moreover, 
HMGA2 directly induces the cyclin A gene CCNA2 as well as its association 
with the transcriptional repressor p120E4F  and through the activation of the 
AP1 transcriptional complex (Tessari et al. 2003). 
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1.2.5.3.3. Modulation of the apoptosis 
HMGA proteins are able to inhibit the apoptosis by regulating the p53 activity 
at a post-transcriptional level. This effect is achieved throught different 
mechanisms. First, HMGA1 regulates the transcription of many p53 effectors, 
such as BCL2-associated X protein and cyclin-dependent kinase inhibitor 1; 
further, it cooperates with p53 to activate the transcription of the p53 inhibitor 
MDM2. It has also found in thyroid cancer cells that HMGA1 associates in 
vivo with p53 family members, and that this interaction results in the inhibition 
of their tumor suppressor activity. (Frasca et al. 2006) Moreover, HMGA1 is 
able to relocalize the proapoptotic p53 activator homeodomain-interacting 
protein kinase 2 (HIPK2) from the nucleus to the cytoplasm, thus preventing its 
interaction with p53 (Pierantoni et al. 2007). 
 
1.2.5.3.4. HMGA proteins impair DNA repair 
As previously described HMGA proteins have been demonstrated to 
preferentially bind to, and inhibit the nucleotide excision repair, UV-induced 
CPDs in stretches of AT-rich DNA both in vitro and in vivo. Further, it has 
been found that HMGA2 binds the promoter of the nucleotide excision-repair 
gene ERCC1 and negatively modulates its activity  (Borrmann et al. 2003). 
Reeves et al. using transcriptional microarrays described a number of genes 
involved in DNA repair that were negatively regulated in MCF7 cells by 
HMGA1 overexpression, suggesting that HMGA proteins can influence DNA 
repair by negatively regulating the transcriptional activity of genes involved in 
various aspects of DNA-damage recognition and removal  (Reeves and Adair 
2005). A role for HMGA1 has been reported also in the double-strand break 
(DSB) repair. Indeed, in 2003 our group reported that HMGA1b protein binds 
to and inhibits the activity of both human and mouse BRCA1 promoters both 
in vitro and in vivo, and that there is an inverse correlation between HMGA1 
and BRCA1 expression in human breast carcinomas. Interestingly, murine ES 
cells with the hmga1 gene deleted showed higher Brca1 mRNA and protein 
levels than do wild-type ES cells and stable transfection of MCF-7 cells with 
the HMGA1b cDNA results in a decrease of BRCA1 gene expression 
(Baldassarre et al. 2003). Consistent with these data, it has been shown that 
HMGA proteins potentiate genotoxic stress induced by different DNA-
damaging agents causing DSBs, such as cisplatin, bleomycin, doxorubicin and 
X-ray irradiation (Baldassarre et al. 2005; Boo et al. 2005). Moreover, the 
cyclin A, indirectly regulated by HMGA1, complexed with the cyclin 
dependent kinase 2, as well in the regulation of DSB repair (Muller-Tidow et 
al. 2004). 
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Figure 1.9. HMGA1 in cancer. A. Schematic representation of p53 
inhibition by HMGA1. B. Schematic illustration of HMGA proteins in 
DNA repair. (From Fusco, Fedele. Nature reviews, 2007) 
 
1.2.5.3.5. Regulation of genes involved in inflammation  
The inflammatory process is known to sustain the tumor growth and it is at the 
basis of the cancer progression. HMGA proteins are able to stimulate 
inflammatory pathways, which in turn can promote cancer progression by 
suppressing apoptosis and inducing proliferation, angiogenesis, invasion and 
metastasis  (Mantovani 2005). Indeed HMGA1 regulates the transcription of a 
number of genes such as inducible nitric oxide (NO) synthase (iNOS, also 
known as NOS2A)  (Perrella et al. 1999), cyclooxygenase 2 (COX2) (Ji et al. 
1998), (Whitley et al. 1994) , E-selectin (Kim et al. 1995), immunoglobulin E 
(Chuvpilo et al. 1993), IL4 (Himes et al. 1996), IL2 (Kim et al. 2001), 
(Mantovani et al. 1998) and granulocyte-macrophage colony-stimulating 
factor. The induction of these genes by HMGA1 likely occurs through its 
ability to enhance the transcriptional activity of nuclear factor κB (NF-κB) 
(Zhang and Verdine 1999) (Bogdan 2001). 
 
1.2.5.3.6. Induction of STAT3 
In 2008, it was highlighted a mechanism by which HMGA proteins have a 
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causal role in hematopoietic malignancies through the regulation of STAT3 
(Hillion et al. 2008). Indeed, the STAT3 gene is a critical downstream target of 
HMGA1a and STAT3 mRNA and protein are up-regulated in fibroblasts 
overexpressing HMGA1a and activated STAT3 recapitulates the transforming 
activity of HMGA1a in fibroblasts. Further, HMGA1a transgenic mice 
developed aggressive lymphoid malignancy and an overexpression of STAT3 
was found in the leukemia cells but not in control cells. Blocking STAT3 
function induced apoptosis in the transgenic leukemia cells but not in controls 
and led to decreased cellular motility and foci formation in human leukemia or 
lymphoma cells. Consistent whith these data, it was found a positive 
correlation between HMGA1a and STAT3 mRNA in primary human leukemia 
samples (Hillion et al. 2008). 
 
1.2.5.3.7. Regulation of the epithelial–mesenchymal transition (EMT) 
The phenomenon of EMT is a common feature of both embryonic development 
and advanced epithelial tumors, where epithelial cells de-differentiate to a 
more fibroblast-like state and regain the ability to invade, migrate and/or 
proliferate in an uncontrolled fashion  (Huber et al. 2005). Several studies 
revealed that in MCF7 cells overexpressing HMGA1, many EMT markers 
were up or down-regulated in function of the HMGA1 overexpression. Further, 
transcriptomic analysis showed that the HMGA2 gene is induced by the Smad 
pathway during EMT and endogenous HMGA2 mediates EMT through the 
TGF-beta pathway, whereas ectopic HMGA2 causes irreversible EMT, 
characterized by severe E-cadherin suppression. Moreover, specific 
knockdown of HMGA2 inhibited cell proliferation, leading to an epithelial-
state transition that restores cell-cell contact due to up-regulation of E-cadherin  
(Thuault et al. 2006), (Thuault et al. 2008). Consistently, an inverse correlation 
between HMGA2- and E-cadherin- positive cells was found in cancer tissues 
(Donato et al. 2004). 
 
1.2.5.3.8. Modulation of miRNA expression 
One mechanism recently highlighted concerns the ability of HMGA1 to 
regulate the expression of miR-181b, which is overexpressed in several 
malignant neoplasias. A direct correlation between HMGA1 and miR-181b 
expression was found in human breast carcinomas. Further, it was shown that 
miR-181b modulates the CBX7 expression, which is generally down-regulated 
in cancer. In particular, it was demonstrated that HMGA proteins are involved 
in the down-regulation of CBX7, which in turn negatively regulates miR-181b 
expression. All toghether these data highlight the existance of a pathway 
involving HMGA1, miR-181b and CBX7, which is at the basis of the cancer 
progression (Mansueto et al. 2010). 
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1.2.5.3.9. Down-regulation of tumor suppressor genes 
Recently, our group has described a role of HMGA1 in the transcriptional 
regulation of HAND1 gene, which codes for a transcription factor crucial for 
differentiation of trophoblast giant cells and heart development. Hand1 was 
found upregulated in hmga1 minus embryonic stem cells and HMGA1 was 
demonstrated to bind directly to its promoter, thus regulating its activity. 
Further, the analysis of human thyroid carcinoma cell lines and tissues 
overexpressing HMGA1, revealed an inverse correlation between HMGA1 and 
HAND1 and it was consistent with the repression of HAND1 and its promoter 
hypermethylation in anaplastic carcinomas. These studies highlighted a role of 
HMGA1 in the silencing of a tumor suppressor gene in later stages of thyroid 
tumor progression, and that it is achieved through the HAND1 promoter 
hypermethylation (Martinez Hoyos et al. 2009).  
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1.3. HMGA PROTEINS AND STEMNESS 
 
The apparent parallels between tumor cells and normal stem cells have 
generated great interest in the possible links between these two classes of cells. 
Feautures of stem cells, such as self-renewal and differentiation capacity can 
find their counterpart in the high proliferative capacity and phenotypic 
plasticity of tumor cells. Moreover, tumor cells often lack the terminal 
differentiation ability that characterizes normal cells. Many regulatory 
networks controlling the function of stem cells may also be active in certain 
tumors. These networks have been the focus of much recent interest, and 
particular attention has been paid to the study of ES cells. 
 
1.3.1. HMGA proteins in stemness networks 
Current evidence indicates that some of the key regulators of stem cells 
identity in ES cells, for example Oct4, Sox2 and Nanog, Stat3 and Lin28, are 
expressed in several human cancer types. These studies have revealed the 
existence of a so called ES-like signature in which HMGA proteins appear as 
master regulator of up and down-regulated genes; the presence of these 
signature directly correlates with a poor prognosis in many human cancers.  
(Ben-Porath et al. 2008), (Shah et al. 2012). 
Pegoraro et al showed that in breast cancer cells, HMGA1 activates stemness 
and key migration-associated genes which are linked to the Wnt/beta-catenin, 
Notch and Pin1/mutant p53 signalling pathways. They studied an HMGA1 
signature in which they found different genes known to be involved in 
processes related to the EMT and the formation of stem cells, including CD24, 
FAM83H, IL1R1, SERPINE1, CALD1, TUBB, LIFR, LEF1 and SET8. 
Interestingly, LEF1 and SET8 are regulatory elements of the Wnt/beta-catenin 
pathway that cooperate in a complex with beta-catenin and function as 
coactivators to sustain the EMT and stem properties (Pegoraro et al. 2013). An 
important role of HMGA proteins in ES cells was highlighted in 2003. Indeed, 
Battista et al found that HMGA1 double knock-out ES cells have reduced self-
renewal ability, demonstrating for the first time the importance of HMGA1 in 
stemness. They reported that Hmga1 null ES cells generate fewer T-cell 
precursors than their wild-type counterpart and the differentiation is 
preferentially into B cells lineage, probably as a consequence of decreased 
interleukin 2 expression and increased interleukin 6 expression. Moreover, a 
lack of HMGA1 expression induces changes in hemopoietic differentiation, 
i.e., a reduced monocyte/macrophage population and an increase in 
megakaryocyte precursor numbers, erythropoiesis, and globin gene expression. 
More recently it has been reported that HMGA1 promotes the cellular 
reprogramming of adult somatic cells to undifferentiated, fully pluripotent stem 
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cells (iPSCs). Since it is known that HMGA1 directly activates specific genes 
involved in tumor growth and progression, including proliferation, migration, 
invasion, angiogenesis, resistance to cell death, immune evasion, and an 
epithelial-mesenchymal transition in cancer cells, it has been explored its role 
also in human embryonic stem cells (hESCs). First, it was found that during 
differentiation, the expression levels of HMGA1 are closely parallel those of 
the embryonic stem cell and pluripotency factors such as NANOG, SOX2 and 
OCT4. Then bone-marrow derived, commercial, adult mesenchymal stem cells 
(MSCs) were transduced by using the standard retroviral reprogramming 
technology with the four Yamanaka factors (OCT4, SOX2, KLF4, and cMYC 
or OSKM ) plus HMGA1 or control. The addition of HMGA1 to OSKM 
resulted in an enhancement of the reprogramming rate, stem cell survival, 
proliferation, or a combination of these factors during iPSC generation (Shah, 
Kerr et al. 2012). According to these findings, HMGA1 has been demonstrated 
able to bind the promoter of pluripotency genes in vivo. 
HMGA1 also drives proliferative changes and polyp formation in the intestines 
of transgenic mice and induces stem-like properties in colon cancer cells 
(Belton et al. 2012). The observation of HMGA1 upregulation in colon cancer 
dates back to 1996, when Fedele et al detected the HMGA1 protein in human 
colorectal cancer cell lines and tissues but not in normal intestinal mucosa 
(Fedele et al. 1996). Subsequently, it was found that HMGA1 protein 
expression was associated with the early stages of the neoplastic 
transformation of colon cells but only rarely with colon cell hyperproliferation 
(Chiappetta et al. 2001). HMGA1 also correlates with the degree of cellular 
atypia in adenomas in transgenic mice and colon cancer cells. Recently, a 
causative role of HMGA1 in proliferative changes, aberrant crypt formation, 
and intestinal polyposis it has been showed in transgenic mice. Further, in 
colon cancer cell lines from poorly differentiated, metastatic tumors, knock-
down of HMGA1 blocks anchorage-independent cell growth, migration, 
invasion and xenograft tumorigenesis while the presence of HMGA1 is 
responsible of the metastatic progression and stem cell-like properties in 
metastatic colon cancer cells (Belton et al. 2012). Interesting findings on the 
role of HMGA1 in regulating stemness came also from the hmga1 null mice 
phenotype. Indeed our group demontrated that the hmga1 double knock-out 
generates pigmy mice. It was compared the tumor susceptibility of mice wild-
type or Hmga1-null mice by using a two-stage chemical skin carcinogenesis 
protocol. Transgenic mice exhibited a decreased number and a delayed onset of 
skin papillomas in comparison with wild-type mice (Visone et al. 2008). A 
possible explanation for all these findings is that the hmga1 knock-out leads to 
the depletion of the stem cell number in transgenic mice, suggesting a role for 
HMGA1 in regulating the stem cell pool during development and growth. 
 
An important role in the maintainance of the stem-like state has been reported 
also for HMGA2. Indeed, by comparing breast tumor-initiating cells (BT-IC) 
and non-BT-IC from 1 degrees breast cancers, Yu et al found that let-7 
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miRNAs were markedly reduced in BT-IC and increased with differentiation. 
The restoration of let-7 by lentivirus infection reduced proliferation, 
mammosphere formation, the proportion of undifferentiated cells in vitro and 
tumor formation and metastasis in NOD/SCID mice, while antagonizing let-7 
by antisense oligonucleotides enhanced in vitro self renewal of non-T-IC. It is 
known, as previously described that HMGA2 is one of the main target of let-7 
miRNA and the specific silencing of HMGA2 induced differentiation in BT-
IC, suggesting its role in the stemness maintainance (Yu et al. 2007). 
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2. AIM OF THE STUDY 
 
HMGA1 is a chromatin-binding protein highly expressed in several malignant 
tumors. It is expressed during embryogenesis, whereas it is absent or at very 
low levels in adult tissues. Several studies have shown a correlation between 
the over-expression of HMGA1 and a highly malignant phenotype (Chiappetta 
et al. 2004). Moreover, it has been exstensively demonstrated that HMGA1 
have a causal role in cell transformation, since blocking HMGA expression 
hampers transformation (Berlingieri et al. 2002). In recent years HMGA 
proteins have emerged as stemness factors; indeed, HMGA1 double knock-out 
ES cells show reduced self-renewal ability (Battista et al. 2003) and HMGA1 
transgenic mice develop polyps and expansion in the stem cell compartment 
(Belton et al. 2012). Further, HMGA1 is a key regulator both in metastatic 
progression and in the maintenance of a stem-like state. 
Given its role in cancer and its involvement in stemness, the aim of this study 
is to clarify whether and how HMGA1 regulate the biology of CSCs. CSCs are 
the real tumor initiating cells and are emerging as election targets for cancer 
eradication therapies. The main purpose of my study has been to characterize 
the molecular machanisms underlying HMGA1 function in CSCs. In particular, 
in this study I focused on the role of HMGA1 in colon cancer stem cells. 
This project, which has been developed during my PhD program, represents 
the main body of my thesis and the subject of the following publication: 
 
Puca F, Colamaio M, Federico A, Gemei M, Tosti N, Uchimura Bastos A, Del 
Vecchio L, Pece S, Battista S and Fusco A. HMGA1 silencing restores normal 
stem cell characteristics in colon cancer stem cells by increasing p53 levels. 
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3. MATERIALS AND METHODS   
3.1. Cell cultures and culture conditions  
Colon tumor stem cell lines were kindly donated by Prof. Ruggero De Maria 
(Istituto Superiore di Sanità, Rome, Italy) and have been described elsewhere, 
together with their culturing conditions (Ricci-Vitiani et al. 2007). Cytokines 
added to the medium includedrecombinant human FGF-basic and EGF 
(Peprotech, Rocky Hill, NJ). HEK293 cells and their culture conditions have 
been described elsewhere. 
  
3.2. Colon samples  
Normal intestinal mucosa was kindly provided by Dott. Marina De Rosa 
(Facoltà di Medicina e Chirurgia, University “Federico II”, Naples, Italy). 
Colon cancer samples have been described elsewhere (Fedele, Bandiera et al. 
1996). 
  
3.3. Quantitative reverse transcription PCR (qRT-PCR)  
Total RNA was reverse transcribed using the QuantiTectâ Reverse 
Transcription Kit (Qiagen), and qRT-PCR was performed by using Power 
SYBRâ Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) 
according to manufacturer’s instructions. G6PD was used to normalise RNA 
levels. The primers used were as follows:  
hsaHMGA1 FW: CAACTCCAGGAAGGAAACCA, 
Hsa HMGA1 hsa Rev: AGGACTCCTGCGAGATGC;  
Hsa_-G6PD_for: 5’-ACAGAGTGAGCCCTTCTTCAA, and  
Hsa_G6PD_rev: 5’-ATAGGAGTTGCGGGCAAAG.  
The 2–DDCt formula was used to calculate the differential gene expression. 
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3.4. Immunostaining and cell sorting  
For cell sorting, the cells were trypsinised, washed twice with PBS, and 
incubated with anti-human CD133 (CD133/2 (293C3)-PE, Miltenyi Biotech) 
for 20 minutes at 4°C. After washing twice with PBS, the cells were FACS 
sorted with a FACScan flow cytometer (Becton Dickinson, San Jose, CA) 
interfaced with a Hewlett-Packard computer (Palo Alto, CA). 
  
3.5. Western blots and antibodies  
Total protein extraction, western blotting, and anti-HMGA1 antibodies have 
been described elsewhere (Melillo et al. 2001). 
Differential nuclear and cytoplasmic cell lysates were obtained as reported 
previously (Schreiber et al. 1989). 
 
The following other antibodies were used: anti-GAPDH (Santa Cruz 
Biotechnology, CA, USA) and anti-p21 (Cell Signaling Technology, 
Inc., Danvers, MA). Anti-NUMB antibodies were obtained from Abcam 
(Cambridge, UK) and were used at 1:5000. Blots were visualised using western 
blotting detection reagents (GE Healthcare, Buckinghamshire, UK). 
  
3.6. Plasmids  
The hairpin RNA interference plasmid for human HMGA1 (pLKO.1-HMGA1, 
TRCN0000018949) and the scramble control pLKO.1-Puro plasmid (SHC002) 
were obtained from Sigma-Aldrich. The sequence of the short hairpin RNA 
targeting the human HMGA1 gene was: 
 5′-
CCGGCAACTCCAGGAAGGAAACCAACTCGAGTTGGTTTCCTTCCTG
GAGTTGTTTTT–3′, (shHMGA1 targets coding region positions 446-466 of 
HMGA1 mRNA transcript variant 2). 
The HMGA1 antisense  consists of the expression vector pRc/CMV 
(Invitrogen) coding sequence of the HMGA1 gene in the antisense orientation 
as described elsewhere (Melillo et al. 2001). 
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The pGL3-luci vector containing the p53 promoter was kindly provided by 
Prof. David Reisman (Center for Colon Cancer Research Tissue Repository, 
University of South Carolina, Columbia) (Durland-Busbice and Reisman, 
2002). 
The pCDNA3.1-HMGA1 expression vector has been described previously 
(Battista et al. 2003). 
  
3.7. Transfections  
CTSCs were electroporated using the Neon® Transfection System 
(Invitrogen). Cells were trypsinised with TrypLE™ Express (GIBCO) and 
counted; 1 x 10 6cells were subjected to the electric field (1400 V, 20 msec; 1 
pulse). 
After 48 h, CTSCs transfected with the short hairpin-expressing constructs 
were selected with puromycin (2 µg/µl). 
  
3.8. Growth curves and TUNEL assay  
Approximately 5 x 103 stably transfected cells were plated in 96-well plates. 
Cells were counted in triplicate at daily intervals with a Burker hemocytometer 
chamber. A TUNEL assay was performed using the In Situ Cell Death 
Detection kit (Roche) according to manufacturer’s instructions. 
 
3.9. Flow cytometry  
After trypsinisation, the cells were washed in PBS and fixed in 70% ethanol. 
Staining for DNA content was performed with 0.1% NP-40, 50 µg/ml 
propidium iodide, and 25 µg/ml ribonuclease A for 20 min. For each 
measurement, 10,000 events were analysed. We used a FACScanto II flow 
cytometer (Becton Dickinson, San Jose, CA). Cell cycle data were analysed 
with the ModFit LT 2.0 software (Verity Software) in a semiautomatic analysis 
procedure. Briefly, we manually selected the cell population in an FSC versus 
SSC dot plot and discarded debris, and then we gated single cells in a PI-height 
versus PI-area dot plot, excluding all doublets. The MODFIT algorithm was 
used to analyse our files, calculating the percentages of cells in each cell cycle 
phase. Statistical analyses to evaluate the significance of the variation in the G1 
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and S phases were performed using the Mann-Whitney U-test. 
  
3.10. Sphere formation assays  
Sphere-forming assays in methylcellulose-based medium were performed as 
previously described (Liu et al. 2011) with some modifications. Briefly, 
medium containing 0.8% methylcellulose was used instead of liquid medium, 
and other conditions were the same as in liquid medium. Three percent 
methylcellulose was purchased from R&D Systems (Minneapolis, USA), and a 
stock solution was made of 2% methylcellulose in DMEM⁄F12. A final 
concentration of 0.8% methylcellulose in DMEM/F12 was used for cell 
culture. Approximately 2 x 104 cells from disaggregated CTSC spheres were 
resuspended in a semisolid medium and plated in 6-well plates. After 7 days, 
the spheres were microscopically visualised, and the diameters were measured. 
Serial passage experiments were conducted as described previously (Cicalese, 
Bonizzi et al. 2009) with some modifications. Briefly, 5,000 cells from 
disaggregated CTSC spheres were plated on 150-mm poly-HEMA-treated cell 
culture plates. After 10 days, the spheres were disaggregated and re-plated at 
the same density. The sphere-forming efficiency (SFE) at each passage was 
obtained by calculating the percentage of the number of spheres divided by the 
number of cells plated. 
  
3.11.  PKH staining and flow cytometric analysis  
PKH staining was performed as previously described (S. Pece et al., Cell 
2010). 
CTSCs were trypsinised, filtered through a 40-µm cell strainer, resuspended in 
PBS (approximately 500,000 cells/ml), labelled with PKH26 (Sigma, 10−7 M, 
5 min), washed twice, and plated. 
For the flow cytometric analysis of PKH26-stained cells, CTSCs were 
trypsinised, filtered through a 40-µm cell strainer, and resuspended in PBS at a 
concentration of 1x106/ml. The cells were subdivided into 5-ml polystyrene 
tubes (Falcon, Becton Dickinson). The BD FACSAria cytometer, equipped 
with four excitation laser lines (633 nm, 488 nm, 405 nm, and 375 nm) (Becton 
Dickinson) was used for FACS analysis, and the BD FacsDIVA software was 
used for data analysis. 
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PKH26 staining was evaluated by selecting the appropriate cell population 
according to the following gating strategy: cells were first gated on physical 
parameters (forward scatter [FSC] and side scatter [SSC]) to exclude most of 
the debris and dead cells; doublets and aggregates were eliminated using the 
FSC-area vs. FSC-height pattern. We gated 10-15% of the brightest PKH26+ 
cells in a PKH26 versus empty channel dot plot. 
 
3.12. Immunofluorescence  
Whole spheres were centrifuged and fixed with 4% paraformaldehyde, 
permeabilised, with 0.1% Triton X-100 and 3% BSA, and stained with anti-
NUMB (kindly donated by Prof. Salvatore Pece and described in (Cicalese et 
al. 2009), followed by anti-mouse Alexa 488 (Jackson Laboratories) 
antibodies. Confocal analysis was performed with a Leica TCS SP2 AOBS 
microscope. 
  
3.13. Luciferase assays  
Transfections for luciferase assays were performed in HEK293 cells using the 
Lipofectamine 2000 method (Invitrogen). For p53 luciferase assays, 
approximately 2 × 105 cells were transiently transfected with 200 ng of pGL3-
luci vector containing the p53 promoter (kindly provided by Professor David 
Reisman, Center for Colon Cancer Research Tissue Repository, University of 
South Carolina, Columbia) and with the indicated amounts of the pCDNA3.1-
HMGA1 expression vector or the corresponding empty vector together with 
0.5 µg of Renilla. Various amounts of the pCDNA3.1 plasmid were co-
transfected to keep the total DNA concentration constant. Transfection 
efficiencies were normalised using Renilla luciferase expression assayed with 
the dual luciferase system (Promega). All transfection experiments were 
performed in duplicate. For NUMB luciferase assays, 2 × 105 cells were 
transiently transfected with 200 ng of GoClone vector containing the NUMB 
promoter (SwitchGear Genomics) or the corresponding empty vector. For 
overexpression was used pCDNA3.1-HMGA1 expression vector. The silencing 
was achieved by using the expression vector pRc/CMV (Invitrogen) coding 
sequence of the HMGA1 gene in the antisense orientation as previously 
described(Melillo, Pierantoni et al. 2001). Transfection efficiencies were 
normalised using the Cypridina TK control construct (pTK-Cluc) expression 
assayed with the BioLux® Cypridina Luciferase Starter Kit according to 
manufacturer instructions. 
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3.14. Chromatin immunoprecipitation  
ChiP was performed as described previously(Federico et al. 2009). As a 
negative control, ChIP experiments were performed with isotype-matched 
preimmune IgG. The promoter occupancy was calculated with respect to the 
input as the percentage of anti-A1-immunoprecipitated DNA subtracted from 
the IgG-immunoprecipitated DNA. The P53 promoter regions assayed for 
HMGA1 binding refer to the nucleotide sequence published in Durland-
Busbice and Reisman, 2002: Region I: nt 401-557; region II: nt 538-650; 
region III: nt 631-751; region IV: nt 767-890; and region V: nt 989-1090. 
The primers for each region were as follows: 
Prom_hQ_tp53_1_Fw CAGGCTTCAGACCTGTCTCC 
Prom_hQ_tp53_1_Rev GCTTTCAGTACATGGAAACGTAA 
  
Prom_hQ_tp53_2_Fw CGTTTCCATGTACTGAAAGCAA 
Prom_hQ_tp53_2_Rev CCCTAACGTTTTCTCCCAGA 
  
Prom_hQ_tp53_3_Fw TCTGGGAGAAAACGTTAGGG 
Prom_hQ_tp53_3_Rev AAGGGTGGAAGGAAGAAAGC 
  
Prom_hQ_tp53_4_Fw GCAGGATTCCTCCAAAATGA 
Prom_hQ_tp53_4_Rev GAGGGTGCAGAGTCAGGATT 
  
Prom_hQ_tp53_5_Fw GTTGATGGGATTGGGGTTTT 
Prom_hQ_tp53_5_Rev AGCTACCTGCTCCCTGGAC 
 
To study the NUMB promoter occupancy of HMGA1 six different regions 
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were selected for AT richeness after in silico analysis. Region I: nt 401-557; 
region II: nt 538-650; region III: nt 631-751; region IV: nt 767-890; and region 
V: nt 989-1090. 
The primers for each region were as follows: 
Prom_hQ_NUMB1_F GAGTGGATCTGGAAGCTGGA 
Prom_hQ_NUMB1_R  CCTCAATGCTAAAGGGCAAA 
 
Prom_hQ_NUMB2_F  TTTGCCCTTTAGCATTGAGG 
Prom_hQ_NUMB2_R  AGCCCTGGGGAGAAAGGTAT 
 
Prom_hQ_NUMB3_F  CAGGGCTTGGAAACACTTCT 
Prom_hQ_NUMB3_R  TCCACTTCTCCAGCTCACTTC 
 
Prom_hQ_NUMB4_F  GCTTCTCCTTGCAGGAAGTG 
Prom_hQ_NUMB4_R  CAGTTTGGTTGCGCAGTAGA 
 
Prom_hQ_NUMB5_F  TCTACTGCGCAACCAAACTG 
Prom_hQ_NUMB5_R  TGGGCAATTCGAAGTTATGA 
 
Prom_hQ_NUMB6_F  TAACTTCGAATTGCCCAACC 
Prom_hQ_NUMB6_R  TAGTATACCCGCCCGTCATC 
 
 
3.15. Chemoresistance to Gefitinib  
The effect of Gefitinib on cell survival was assessed by plating single cells in 
96-well plates at a density of 3 x 103 cells/well. CTSCs were treated with 
different concentrations of Gefitinib (5, 10 and 15 µM); DMSO was used as 
control. After 24, 48, 72 and 96 hours the cell viability was assessed by using 
the CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega) 
according to the manufacturer instructions. After incubating for 3 hours at 
37°C, the absorbance was read at a wavelenght of 490 nm by using a 
Microplate Reader 480 (Biorad). Results are expressed as absorbance at 490 
nm. 
 
3.16. Statistical analysis  
Statistical analyses were performed using the Kruskal-Wallis test or the Mann-
Whitney U-test. If the Kruskal-Wallis test was positive (P<0.05), a pairwise 
comparison of subgroups was performed using Dunn's or Conover post-hoc 
test. 
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4. RESULTS   
4.1. HMGA1 is overexpressed in CTSCs and in the CD133+ sub-
population 
 
We first analysed HMGA1 expression by Western Blot in normal colonic 
mucosa (NM), colon cancer samples, colon cancer cell lines, and CTSC lines. 
As shown in Fig. 4.1, HMGA1 is expressed at higher levels in CTSCs 
compared with NM, colon cancer tissues (Tumor #3), and colon cancer cell 
lines (GEO, SW480, SW48, CACO2). At the protein level, HMGA1 was 
undetectable in NM (Fig. 4.1.A), whereas it was expressed in colon cancer 
samples (Tumor #3), in 3 colon cancer cell lines (SW48, SW480 and CACO2), 
and CTSCs (CTSC#18 and CTSC#1.1), which exhibited the highest HMGA1 
expression. Interestingly, when CTSCs were stained for the cancer stem cell 
marker CD133 and then sorted, HMGA1 expression was enriched in CD133+ 
cells (Fig. 4.1.B). These data indicate that HMGA1 is overexpressed in CTSCs 
and is more abundant in stem cells than in precursors.  
 
          
         
 
 
Figure 4.1. HMGA1 expression in CTSCs 
A) Western blot for HMGA1 in normal colonic mucosa (NM), colon cancer 
sample (T#3), colon tumor-derived cell lines, SW48, SW480, GEO, and 
CACO2, and colon tumor stem cells (CTSC#18 and CTSC#1.1). B) Western 
blot for HMGA1 in unsorted CTSC#18 and sorted CD133+ and CD133- 
cells. GAPDH was used as a loading control. 
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4.2. HMGA1 knockdown impairs CTSCs growth and induces apoptosis 
 
To understand the role of HMGA1 in CTSC, we silenced HMGA1 expression 
in the CTCS#18 cell line, using a short hairpin interfering construct (see the 
Materials and Methods section), leading to an HMGA1 knockdown efficiency 
of approximately 50%-80%  in stable transfectants (Fig. 4.2.A). Then, we 
characterized interfered CTSCs at different levels. Growth curves performed 
on single-cell suspensions demonstrated that the knockdown of HMGA1 
significantly reduced CTSC proliferation. (Fig. 4.2.B) 
                                   
             A 
                            
 
 
 
              B 
                
Figure 4.2. HMGA1 interference in CTSCs. A) Western blots for HMGA1 in 
untransfected, HMGA1-knockdown (CTSC_shA1), and scramble-
transfected (CTSC_ctrl) cells. GAPDH is used as a loading control.  
B) Growth curve of CTSCs stably transfected with HMGA1 antisense 
(CTSC_antiA1) and empty vector-RcCMV (CTSC_ctrl). Data are the mean 
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value ± SD of one representative experiment, performed in quadruplicate 
(*, p < 0.05, Mann-Whitney U-test). 
 
 
The analysis of cell cycle progression, performed by flow cytometric analysis, 
demonstrated that HMGA1 knockdown reproducibly altered cell cycle 
progression, inducing a mean increase of 5% (P < 0.05) in the G1 phase 
population and a concomitant mean reduction of 4% (P < 0.05) in the S phase 
(Fig. 4.3).  
As previously reported (Shah, Kerr et al. 2012), HMGA1 knockdown reduced 
the expression of stem cell/pluripotency genes, such as SOX2 and NANOG 
(Fig. 4.4). 
 
 
 
                 
Figure 4.3. Cell cycle analysis. A) Histogram of the FACS analysis in 
CTSC_ctrl and CTSC_shA1 cells. Data are the mean value ± SD of 3 
independent experiments. 
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Figure 4.4. Differentiation markers analysis. qRT-PCR for SOX2 and 
NANOG gene expression in CTSC_ctrl and CTCS_shA1 cells. The 
expression level of each gene was normalized to the G6PD gene expression 
(*, p < 0.05, Mann-Whitney U-test). 
 
 
Because the alteration of the cell cycle only partially accounts for the reduction 
in CTSC proliferation induced by HMGA1 knockdown, we investigated 
apoptotic cell death. TUNEL (terminal deoxynucleotidyl transferase dUTP 
nick-end labeling) assays performed on stable transfectants exhibited a 7-fold 
increase in apoptotic cell numbers in CTSC_shA1 with respect to control cells 
(Fig. 4.5.A, B). These data suggest that, as in other cell systems (Fedele and 
Fusco 2010), HMGA1 plays a key role in CTSC proliferation by affecting cell 
cycle progression and apoptosis.  
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Figure 4.5. HMGA1 knockdown effects on apoptosis in CTSCs.  
A) Fluorescence micrographs of TUNEL assays performed on non-
transfected CTSCs, CTSC_ctrl and CTSC_shA1 cells, double-stained with 
Hoechst dye (left) to identify total nuclei and with TMR red UTP (right) to 
identify apoptotic, TUNEL-positive cells. B) Bar chart representation of the 
number of TUNEL-positive cells per 100 Hoechst-positive nuclei in the 
samples shown in A. Each bar represents the mean ± SD of 10 arbitrary 
fields. An asterisk indicates the significance of the difference between 
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CTSC_shA1 and CTSC_ctrl (*, p = 0.0014; Kruskal-Wallis test followed by 
Dunn's post-hoc test). 
 
 
4.3. HMGA1 silencing impairs CTSC self-renewal and sphere-forming 
efficiency in serial passages 
CTSCs, as other types of cancer stem cells, are characterised by their ability to 
form spheres in suspension cultures (Ricci-Vitiani et al. 2007) or in a semisolid 
medium. The number of spheres reflects the quantity of cells capable of in 
vitro self-renewal, whereas the number of cells/sphere measures the self-
renewal capacity of each sphere-generating cell (Dontu et al. 2004). Therefore, 
we assayed the ability of cells with reduced HMGA expression to form spheres 
in methylcellulose-based medium. A dramatic reduction in the number of 
spheres (Fig. 4.6.A,B) and in their diameter (Fig. 4.6.C) was observed in 
CTSC_shA1 cells compared with control CTSC_ctrl, thus indicating that 
HMGA1-interference affects CTSC self-renewal.  
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              C                
                       
Figure 4.6. Effects of HMGA1 knockdown on the sphere-formation 
ability of CTSCs. A) Sphere formation was determined by plating single 
cells in methylcellulose-based medium. We characterized spheres formed 
from CTSCs silenced for HMGA1 compared to control. B) The diagram 
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represents the average number of spheres 7 days after plating. Spheres 
with diameters > 70 µm were counted in each of 10 representative fields. 
Triple asterisks indicate the significance of the difference in the number of 
spheres formed by CSC_ctrl and CTSC_shA1 cells (***, p < 0.001; Mann-
Whitney U-test). 
C) Diagram showing the sphere diameter distribution in CTSC_ctrl and 
CTSC_shA1 cells. Each bar represents the mean ± SD diameter found in 10 
representative fields. Mann-Whitney U-test.  
 
 
CSCs are known to differ from normal stem cells both in their deregulated self-
renewal and cell division pattern, and an evaluation of their sphere-formation 
efficiency (SFE) in serial passages allows the assessment of the rate at which 
CSCs divide symmetrically (Dontu, El-Ashry et al. 2004) (Deleyrolle et al. 
2011). As shown in Fig. 4.7., the SFE of CTSC_shA1 cells decreased at every 
passage, whereas the number of spheres derived from parental (not shown) or 
CTSC_ctrl cells increased progressively.  
 
 
            
Figure 4.7. Sphere forming efficiency in CTSCs silenced for HMGA1. 
Diagram showing the sphere-formation efficiency (SFE) ± SD in scramble- 
and HMGA1-knockdown CTSCs in serial passages (from F0 to F3). The 
spheres were disaggregated every 10 days. SFE is measured as the 
percentage of the number of spheres per plated cell at every passage. The 
data represent the results of two independent experiments.  
 
 
Interestingly, previous studies have demonstrated that the knock-out of p53 
leads to increases in SFE and the symmetric division of mammary stem cells in 
serial passages, whereas the p53 stabiliser Nutlin-3 is able to reduce the SFE of 
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ErbB2 mammary stem cells in serial passages (Cicalese et al. 2009). Consistent 
with these studies, we observed that the treatment of parental CTSC#18 with 5 
µM Nutlin-3 was able to maintain the SFE over subsequent passages, similar to 
what was observed for CTSC_shA1 cells. Conversely, SFE increased in 
DMSO-treated cells. Therefore, these results indicate that HMGA1 silencing 
not only restores the ability to divide asymmetrically but also exhibits a more 
dramatic effect than p53 stabilisation alone.  
 
 
              
Figure 4.8. Sphere forming efficiency in CTSCs after p53 stabilization 
with Nutlin-3. Sphere-formation efficiency (SFE) in parental CTSC#18 
cells treated with DMSO or Nutlin-3 (5 µM) in serial passages (from F0 to 
F3). Spheres were disaggregated every 7 days. The data represent the 
mean value ± SD of two independent experiments.  
 
 
 
4.4. HMGA1 silencing induces quiescence in CSCs 
  
Long-term label retention of PKH26 dye is frequently used as an indicator of 
normal stem cell quiescence (Pece et al. 2010). Indeed, rapidly and 
symmetrically dividing CSCs tend to quickly lose PKH26 (Cicalese, Bonizzi et 
al. 2009), which irreversibly binds to the lipid bilayers on cell membranes and 
is equally distributed among daughter cells during each cell division. 
Conversely, normal quiescent stem cells divide asymmetrically in one 
proliferating progenitor and one self-renewing PKH26-retaining quiescent stem 
cell. Therefore, we stained CTSC_shA1 and control CTSC_ctrl cells with 
PKH26 and performed a FACS analysis after 10 days. As shown in Fig. 4.9.A, 
knockdown of HMGA1 expression led to a drastic increase in PKH26bright cells 
(1.5 % in CTSC_ctrl cells versus 4.8 % in CTSC_shA1 cells), suggesting that 
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the reduction in HMGA1 expression confers properties of quiescence to the 
stem cell compartment. Interestingly, very similar results were obtained when 
HMGA1-knockdown brain tumor stem cells (BTSCs) were stained with 
PKH26 (Colamaio et al., manuscript in preparation).  
 
 
 
A 
     
 
 
 
B 
                           
 
Figure 4.9. HMGA1 knockdown induces stem cell quiescence. 
A) FACS plots of double-coloured (PKH26-phycoerythrin [PE] and 
fluorescein isothiocyanate [FITC-A]) CTSC_ctrl and CTSC_shA1 cells (one 
representative experiment). The left-most panel shows cells non-stained 
with PKH26, gated on physical parameters (forward scatter [FSC] and side 
scatter [SSC]) to exclude most of the debris and dead cells.  
B) Mean percentage of PKH26bright cells in CTSC_ctrl and CTSC_shA1 
populations, after 10 days from staining. Each bar represents the mean ± 
SD of 5 independent experiments (*, p < 0,05; Mann-Whitney U-test). 
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4.5. HMGA1 regulates p53 expression at the transcriptional level 
 
Because it has been previously shown that an imbalance between asymmetric 
and symmetric division can be determined by loss of the p53 tumor suppressor 
(Cicalese, Bonizzi et al. 2009), we analysed p53 expression in CTSC_shA1 
cells. Western blots performed on untransfected, scramble-transfected, and 
HMGA1–knockdown CTSCs demonstrated that the downregulation of 
HMGA1 increased p53 protein expression  and was associated with an increase 
in the p53-regulated p21 protein (Fig. 4.10), indicating the presence of a 
functional p53. 
                                 
            
Figure 4.10. p53 expression in CTSCs interfered for HMGA1. Western 
blot analysis for p53 and p21 expression in non-transfected, HMGA1-
knockdown, and scramble-transfected cells. GAPDH was used as a 
loading control.  
 
 
Then, to verify whether the HMGA1 knock down affects the p53 expression 
also at the transcriptional level, we analyzed the p53 mRNA level by qRT-PCR 
in CTSCs_shA1 compared to CTSCs_ctrl. We found that the silencing of 
HMGA1 induces an increased expression of p53 also at the mRNA level. 
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Figure 4.11. p53 mRNA level. qRT-PCR for p53 gene expression in 
CTSC_ctrl and CTCS_shA1 cells. The expression level of each gene was 
normalized to the G6PD gene expression (*  p < 0.05, Wilcoxon signed-rank 
test). 
 
Subsequently, to assess the direct action of HMGA1 on p53 transcription, we 
evaluated HMGA1 protein binding to the p53 promoter in vivo by performing 
ChIP assays. Therefore, CTSC_ctrl and CTSC_shA1 cells were cross-linked 
and immunoprecipitated with anti-HMGA1 or anti-IgG antibodies. 
Immunoprecipitation of chromatin was then analysed by quantitative PCR, 
using primers spanning 5 different regions of the p53 promoter (see the 
Materials and Methods section). Occupancy of the p53 promoter regions II and 
III by HMGA1 was clearly detectable, whereas no amplification was observed 
in regions I, IV, and V, indicating the specificity of the binding to regions II 
and III. Conversely, CTSC_shA1 cells exhibited a negligible enrichment for 
regions II and III and no enrichment at all for the remaining regions (Fig. 4.12). 
These results indicate that HMGA1 protein binds the p53 promoter region in 
vivo. 
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Figure 4.12. HMGA1 direct binding of the p53 promoter. ChIP assay, 
revealed by qPCR, detecting the in vivo binding of HMGA1 to the 5 sub-
regions in the p53 promoter in CTSC_ctrl and CTSC_shA1 extracts. The 
relative occupancy of the p53 promoter regions by HMGA1 is indicated as 
vertical bars. GAPDH promoter amplicon was used as a negative control. 
 
 
To define the functional importance of HMGA1 binding to the p53 promoter, 
we evaluated the activity of the p53 promoter in the presence or absence of 
HMGA1 by performing luciferase assays. Therefore, HEK293 cells were 
transfected with a reporter gene construct carrying the human p53 promoter 
(Durland-Busbice and Reisman 2002) or a control backbone vector (pGL3-
basic) in the presence of an HMGA1-expressing construct. As shown in Fig. 
4.13, HMGA1 repressed the p53 promoter, and this effect was dose-dependent. 
Consistently, this repressive effect was abolished by the pharmacological 
blocking of the HMGA1-DNA interaction with distamycin (not shown), a drug 
known to displace HMGA1 from its AT-rich DNA regions (Smith and 
Buchmueller 2011). Therefore, these results clearly demonstrate that HMGA1 
transcriptionally regulates p53 expression.  
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Figure 4.13. HMGA1 directly regulates the p53 promoter. Luciferase 
activity of the p53 promoter in HEK 293 cells in the presence or absence of 
an HMGA1-expressing vector. The amounts of the HMGA1-expressing 
vector are indicated. The data are the results of three independent 
experiments performed in duplicate. The relative luciferase activity was 
normalised with Renilla luciferase and was expressed as the fold induction 
over the activity of the p53 promoter (*, p < 0.05). pGL3-basic activity in 
the presence or absence of the HMGA1-expressing construct was used as a 
negative control.  
 
 
 
4.6. HMGA1 silencing induces asymmetric distribution of NUMB in CSCs  
 
Asymmetric cell division can be demonstrated by the asymmetric partitioning 
of the cell fate determinant NUMB (Pece, Tosoni et al. 2010). During 
asymmetric cell division, the part of the cell that inherits high levels of NUMB 
will undergo differentiation, whereas the part that inherits low levels will 
produce a stem cell; conversely, in symmetrically dividing CSCs, NUMB is 
expressed at lower levels and is uniformly distributed in such a way that both 
daughter cells will be equal in terms of NUMB expression and function 
(Morrison and Kimble 2006).  
Therefore, we analysed NUMB expression/distribution in HMGA1-knockdown 
and control cells. Western blot analysis for NUMB revealed higher levels of 
NUMB in CTSC_shA1 cells with respect to untransfected and CTSC_ctrl cells 
(Fig. 4.14).  
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Figure 4.14. NUMB expression in CTSCs interfered for HMGA1. Western 
blot for NUMB in non-transfected, CTSC_shA1, and CTSC_ctrl cells. 
GAPDH was used as a loading control.  
 
 
Moreover, immunofluorescence of the spheres (Fig. 4.15.A) demonstrated that 
whereas NUMB was distributed almost uniformly in the cell cytoplasm of 
CTSC_ctrl cells, it formed an asymmetric punctuate crescent close to the cell 
membrane in CTSC_shA1 cells, where it also undergoes partial nuclear 
localisation (asterisks). The frequency of NUMB crescents increased from 
approximately 6% in control cells, to approximately 32% in CTSC_shA1 cells 
(p = 0,0048) (Fig. 4.15.B). Together, these data demonstrate that HMGA1-
silencing restores normal stem cell properties in CSCs, such as quiescence and 
asymmetric division. 
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Figure 4.15. NUMB detection by immunofluorescence. A. 
Immunofluorescence for NUMB in CTSC_ctrl (left) and CTSC_shA1 (right) 
CTSCs. The nuclei are stained in blue with DAPI. Arrows denote the 
crescent-shaped NUMB distribution whereas asterisks indicate nuclear-
localised NUMB. B. The histogram shows the percentage of cells with 
crescent-shaped, asymmetric NUMB distribution, obtained in 
immunofluorescence analyses. Data are the mean value ± SD of 7 arbitrary 
fields for each sample. (** , p = 0.0048; Mann-Whitney U-test). 
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4.7. HMGA1 regulates NUMB expression at the transcriptional level 
 
Since HMGA1 knock-down induces an increased expression of NUMB in 
CTSCs, we asked whether HMGA1 could have a role in the transcriptional 
regulation of NUMB as well. 
First, we analyzed NUMB expression at mRNA level. qRT-PCR analyses 
demonstrated an increased expression of NUMB in CTSCs_shA1 compared to 
CTSCs_ctrl (Fig. 4.16). 
 
                       
 
Figure 4.16. NUMB mRNA level. qRT-PCR for NUMB gene expression in 
CTSC_ctrl and CTCS_shA1 cells. The expression level of each gene was 
normalized to the G6PD gene expression (*  p < 0.05, Wilcoxon signed-rank 
test). 
  
Then, to assess whether HMGA1 directly binds the NUMB promoter, we 
performed ChIP assays. CTSC_ctrl and CTSC_shA1 cells were cross-linked 
and immunoprecipitated with anti-HMGA1 or anti-IgG antibodies. In this case, 
immunoprecipitation of chromatin was analysed by quantitative PCR, using 
primers spanning 6 different regions of the NUMB promoter (see Materials and 
Methods).  
We detected occupancy of the NUMB promoter regions I and II by HMGA1 
(Fig. 4.17), whereas no amplification was observed in the remaining regions, 
indicating the specificity of the binding. Conversely, CTSC_shA1 cells 
exhibited a negligible enrichment for regions I and II and no enrichment at all 
for the remaining regions. These results indicate that HMGA1 protein binds 
also the NUMB promoter in vivo.  
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Figure 4.17. HMGA1 direct binding of the NUMB promoter. ChIP assay, 
revealed by qPCR, detecting the in vivo binding of HMGA1 to the 6 sub-
regions in the NUMB promoter in CTSC_ctrl and CTSC_shA1 extracts. The 
relative occupancy of the NUMB promoter regions by HMGA1 is indicated 
as vertical bars. GAPDH promoter amplicon was used as a negative 
control. 
 
The functional significance of the binding of HMGA1 to the NUMB promoter 
was examined by luciferase assays, performed in HEK293 cells transfected 
with a NUMB promoter-reporter construct, in presence of a vector expressing 
the HMGA1 cDNA in sense or antisense orientation (see Materials and 
Methods). Strikingly, we found that the silencing of HMGA1 induced an 
increase of the luciferase activity, whereas its overexpression reduced the 
reporter activity (Fig. 4.18). These data clearly indicate that HMGA1 is able to 
negatively control  NUMB expression at transcriptional level. 
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Figure. 4.18. Regulation of NUMB promoter by HMGA1. Luciferase 
activity of the NUMB promoter (NUMB luc) in HEK 293 cells in presence 
of the HMGA1-antisense (AntiA1), the HMGA1-expressing (HMGA1) 
vector or the corresponding empty vectors. NUMB-specific effects are 
shown as fold induction respect the NUMB promoter activity. Values are 
average of four independent experiments and error bars denote standard 
deviation (* p <0.05; ** p <0.01; *** p <0.001, Kruskal-Wallis test, Conover 
post-hoc test). 
 
 
4.8. HMGA1 modulates NUMB localization in CTSCs 
 
Since, as shown above, immunofluorescence suggested that HMGA1 knock-
down induced NUMB nuclear delocalization, we better investigated the 
different distribution of NUMB in CTSCs silenced for HMGA1 by Western 
blot analysis of nuclear/cytoplasmic extracts.  
We found that there is no variation of NUMB expression levels in the 
cytoplasmic extracts in CTSC_shA1 compared to CTSC_ctrl; conversely 
NUMB was found increased in the nuclei of HMGA1 knock-down cells (Fig. 
4.19).  
These preliminary data suggest that, besides its effect on the transcriptional 
regulation, HMGA1 could be implicated also in the regulation of NUMB 
localization. Further experiments are required to confirm these data and to 
better characterize the mechanism by which HMGA1 could achieve this 
function. 
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Figure 4.19. NUMB relocalization in CTSCs after HMGA1 silencing. 
Western blot analysis for NUMB expression in fractionated protein extract 
from CTSCs_ctrl and CTSC_shA1. 8 µg of cytoplasmic and 20 µg of nuclear 
extracts were loaded. Sp1 was used as a loading control for nuclear protein 
extracts. Tubulin was used as a loading control for cytoplasmic extracts.  
 
 
4.9. HMGA1 knock-down enhances chemosensitivity to Gefitinib in 
CTSCs 
 
Several studies have found a correlation between HMGA1 and 
chemoresistence. This is due, at least in part, to its involvement in anti-
apoptotic pathways. Since CSCs, because of their resistance to conventional 
therapies, are identified as responsible of tumor relapse after chemoterapy, we 
decided to investigate whether HMGA1 could be related to this CSCs feature. 
To this aim, we treated CTSCs with Gefitinib, used in colon cancer treatment. 
We evaluated the cell proliferation after treatment with Gefitinib 
concentrations ranging from 5 to 15 µM. Interestingly, we found that 
CTSCs_ctrl showed resistance to 5 µM and 10 µM and sensitivity to drug 
starting from 15 µM; conversely, in CTSCs_shA1 we observed a cytotoxic 
effect starting from 10 µM and increasing at 15 µM (Fig. 4.20). These data 
suggest that HMGA1 contributes to determine the resistance of CTSCs to a 
drug conventionally used in clinical practice.  
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A                       DMSO                          B            5 µM Gefitinib 
 
C                 10 µM Gefitinib                 D            15 µM Gefitinib 
 
 
Figure 4.20. HMGA1 interference on chemoresistance.  
Growth curve of scramble (CTSC_ctrl) and HMGA1-knockdown 
(CTSC_shA1) CTSCs treated with Gefitinib at different concentrations. A. 
CTSCs treated with DMSO, as control. B. Treatment with 5 µM C. 10 µM 
D. 15 µM. Data are the mean value ± SD of one representative experiment, 
performed in quadruplicate. 
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5. DISCUSSION 
 
CSCs are a distinct subset of cancer cells with the ability to self-renew through 
symmetric division and to generate a repertoire of various cell types, thus 
initiating and perpetuating tumor growth. CSCs are often endowed with 
distinctive surface markers, such as CD133, which, in colon cancer and in 
gliomas and other cancers, decorates tumor-initiating cells versus cells that are 
unable to initiate tumors in transplantation experiments (O’Brien et al., 2007). 
In human cancers, CSCs have been demonstrated to be a major cause of cancer 
treatment resistance, invasion, metastasis, and relapse. Thus, eliminating 
cancer cells with stem cell properties is of prime importance for the successful 
treatment of cancer, regardless of the tissue of origin (O'Brien et al. 2007). 
Recent studies have suggested a unique role for the HMGA1 protein as a 
master regulator in both cancer stem cells and normal embryonic stem cells. 
Indeed, it has been recently shown that HMGA1 reprograms somatic cells into 
pluripotent stem cells, by inducing stem cell transcriptional networks (Shah et 
al. 2012). Moreover, it has been directly or indirectly demonstrated that 
HMGA1 proteins are tightly associated with stemness (Belton et al. 2012), and 
have a critical role in EMT transition (Pegoraro et al. 2013). 
Here, we present a new work unveiling a central role for HMGA1 in CSCs 
self-renewal. 
First of all, we demonstrate that HMGA1 is enriched in colon CSCs compared 
to tumors and cancer cell lines; moreover, in CSCs, it is more abundantly 
expressed in CD133+ cells than in CD133- cells, strengthening its association 
with tumor initiating cells.  
We show that the knockdown of the HMGA1 protein in colon CSCs (CTSCs) 
induces a drastic reduction in proliferation, a slight increase in G1 phase and a 
more evident increase in apoptosis, consistently with our previous findings in 
different cell systems (Baldassarre et al. 2001). Moreover, CTSC_shA1 regain 
two properties typical of normal adult stem cells: reduced SFE, suggestive of a 
reduction in symmetric self-renewing divisions (Deleyrolle et al. 2011), and 
increased percentage (and brightness) of PKH26 positive cells, which is 
suggestive of increased quiescence. Quiescence is one of the most important 
characteristics distinguishing normal SCs from CSCs. 
Normal stem cells are characterized by a balance between symmetric and 
asymmetric divisions. In a typical outcome of an asymmetric division, the stem 
cell generates a copy of itself, which retains self-renewing ability and 
differentiation potential, and one daughter cell that enters the path of 
differentiation. Thus, by balancing self-renewal with differentiation, 
asymmetric division maintains the stem and progenitor cell pool while 
allowing the generation of diverse functional cells (Gomez-Lopez et al. 2014), 
so that the number of stem cells in the stem cell niche do not change overtime; 
in in vitro cultures this property results in a progressive decrease of their 
efficiency to form spheres, in serial passages. Conversely, in cancer stem cells 
the balance between symmetric and asymmetric divisions is completely 
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compromised. CSCs mainly divide symmetrically and, due to their 
proliferation potential, the number of stem cells increases over generations. 
Genetic cancerogenic mutations affect molecular pathways that are important 
regulators of asymmetric cell division. A genome-wide screen for micro-
deletions across a range of primary and cultured human tumor cells identified 
the deletion of polarity regulators in numerous human epithelial tumor cells. 
Such deletions include PARD6 (PAR6) in lung cancer, PARD3 (PAR3) in 
lung, head and neck, esophagus, prostate and bladder cancers, and DLG2 in 
lung and cervical cancers (Kunnev et al. 2009). Disruption of asymmetric cell 
divisions leads to aberrant self-renewal and impairs differentiation, and could 
therefore constitute an early step in the neoplastic transformation of stem and 
progenitor cells.  
 
Our data, and data from other laboratories, suggest a pivotal role of HMGA1 in 
regulating self renewal and the symmetric/asymmetric division ratio in CTSCs. 
Indeed, CTSCs, isolated from patients and stabilized in suspension cultures, 
behave exactly as expected for cancer stem cells, since their efficiency in 
forming spheres in culture increases over generations. The reduction in the 
SFE and proliferation found in HMGA1 knock-down cells makes CTSCs more 
similar to normal stem cells and demonstrate the importance of detecting 
HMGA1 in both diagnosis and choice of the therapeutic strategy, since higher 
levels of HMGA1 in tumors could imply the presence of more CSCs, possibly 
endowed with higher proliferation ability and aggressiveness. Notably, we 
have achieved comparable results, in terms of SFE reduction and PKH26 
increase, in HMGA1-interfered BTSCs, suggesting a critical role of the 
HMGA1 protein in the regulation of CSCs of different tissue origin.  
 
From our data, it can be postulated that HMGA1 overexpression levels in 
normal stem cells might induce symmetric division and open the way to the 
transformation process. As a corollary, one would speculate that the lack of 
HMGA1 would protect from cancer initiation, due to the reduction in the cell 
population responsible of tumor initiation. Actually, even if a reduction in the 
stem cell compartment has not been thoroughly investigated, it has previously 
shown in our lab that Hmga1 null mice are less susceptible to chemically 
induced skin carcinogenesis (Visone et al. 2008), possibly due to a lower 
number of stem cells/potentially tumor initiating cells. 
Recently, it has been demonstrated that ErbB2 transgenic mice harbor CSCs 
with increased frequency of self-renewing divisions, higher replicative 
potential and preponderance of symmetric versus asymmetric division, 
highlighted by  the symmetric distribution of the cell fate determinant NUMB, 
compared to stem cells from wild-type mice (Cicalese et al. 2009).  In these 
cells,  Nutlin 3-mediated stabilization of p53 was able to restore asymmetric 
division, also evidenced by the recovering of the asymmetric distribution of 
NUMB (Cicalese et al. 2009). The similarity of the CTSC_shA1 phenotype 
with those obtained by treating CSCs with Nutlin-3 and the tight correlation 
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between HMGA1 and ErbB2 expression (Chiappetta et al. 2004), prompted us 
to investigate the effect of HMGA1 interference on the HMGA1-p53 axis. 
Strikingly, we found that CTSC_shA1 cells have increased p53 (and p21cip) 
expression levels, compared to control cells. Further, we found that the 
HMGA1 knock-down induces also an increase of the p53 mRNA level. 
Luciferase assays and chromatin immunoprecipitation analysis revealed that 
HMGA1 exerts its regulation on p53 expression at transcriptional level, by 
binding to its promoter region. Therefore, the restoration of p53 functions 
induced by HMGA1 knockdown likely accounts for the effects of the HMGA1 
silencing on CSC cells. Accordingly, in p53-null BTSCs, HMGA1 interference 
does not affect sphere formation ability, even though it has dramatic 
consequences on CSCs migration and differentiation (Colamaio et al., 
manuscript in preparation).  
On the other hand, the stabilization of p53 in CTSCs by treating cells with 
Nutlin-3 also affected their self-renewal ability, even though with lower 
efficacy than HMGA1 knock-down. Indeed, the SFE of Nutlin-treated CTSCs 
remains constant overtime, whereas it decreases in HMGA1 knock-down 
CTSCs, probably due to the additional effects on apoptosis (Cicalese et al. 
2009).  
Even though we demonstrate, for the first time, a direct role of HMGA1 on p53 
activity in CSCs, the inhibitory activity of HMGA1 on p53 at different levels 
and in different cell systems, is not new: HMGA1 has been shown to interfere 
with p53-mediated transcription of p53 effectors Bax and p21(waf1) and to 
transcriptionally activate the p53 inhibitor mdm2; at a second level of 
regulation, HMGA1 inhibits p53 by cytoplasmic relocalization of its 
proapoptotic activator HIPK2. Therefore, the data presented here, add a new 
level of regulation on the already described HMGA1-dependent p53 control. 
rev in (Fedele and Fusco 2010). 
All these findings concerning the regulation of the asymmetric cell division 
exerted by HMGA1 and the tight correlation with p53 prompted us to further 
investigate the importance of the HMGA1 knock-down on other molecular 
regulators of polarity and cell fate.  
Mounting evidence points to a role for the cell-fate determinant NUMB as a 
tumor suppressor in distinct types of human cancers and recently this role has 
been correlated with its function in the regulation of the asymmetric cell 
division. In breast cancers, NUMB protein levels are frequently reduced or lost 
and inversely correlate with tumor grade and patient prognosis. In primary 
breast tumor cell cultures, those with low or no NUMB expression, referred to 
as class 1, not only display increased NOTCH activity but also a reduction of 
p53 protein levels. Forced-expression of NUMB in class 1 cells significantly 
reduces NOTCH activity and cell proliferation and restores normal p53 levels 
(Gomez-Lopez et al. 2014).  
Cicalese et al. demonstrated that in primary ErbB2-driven mouse mammary 
carcinoma cells, p53 is unstable, and attenuated p53 levels switch the mode of 
    73 
cell division from asymmetric to symmetric, leading to geometric cell 
expansion (Cicalese et al. 2009). Although it is not clear whether in this model 
the levels of NUMB protein are also affected, these observations suggest that 
downregulation of NUMB-p53 in human breast cancers may cause a bias 
towards symmetric divisions. 
Interestingly, it has been shown an interaction in vivo between overexpressed 
NUMB and HDM2; the latter, as already mentioned, is transcriptionally 
regulated by HMGA1 (Fedele and Fusco 2010). Colaluca et al. demonstrated 
that NUMB physically interacts with and stabilizes p53, by preventing its 
ubiquitination and degradation induced by the E3 ubiquitin ligase HDM2. 
Indeed, NUMB co-immunoprecipitates with p53 and these data led to postulate 
the existence in vivo of a tricomplex NUMB–HDM2–p53. In vitro binding 
assays confirmed the direct interaction between the three proteins. The 
presence of Nutlin-3, which inhibits the HDM2–p53 interaction, prevented the 
formation of the HDM2–p53 complex, but not of the HDM2–NUMB or p53–
NUMB complexes. Thus, the NUMB–p53 and NUMB–HDM2 surfaces of 
interaction are distinct, at least in part, from that of the HDM2–p53 interaction, 
confirming the formation of the tricomplex in vivo. (Colaluca et al. 2008) 
Reduced NUMB levels are also observed during the progression of human 
chronic myeloid leukemia (CML) to blast crisis and this is associated with 
increased NOTCH signaling and reduced p53 activity (Ito et al. 2010). 
Consistently with all these findings, here we report an increased expression of 
NUMB in the CTSC after the HMGA1 knock-down. We confirmed a role for 
HMGA1 in regulating NUMB at transcriptional level by revealing both a 
physical interaction with the NUMB promoter by ChIP assay, and a functional 
regulation by luciferase assays. Moreover, in CTSC_shA1, we observed a 
different distribution of NUMB. Immunofluorescence of the spheres 
demonstrated that whereas NUMB was distributed almost uniformly in the cell 
cytoplasm of CTSC_ctrl cells, it formed an asymmetric punctuate crescent 
close to the cell membrane in CTSC_shA1 cells.  The frequency of NUMB 
crescents increased from approximately 6% in control cells, to approximately 
32% in CTSC_shA1 cells, indicating an unexpected effect of HMGA1 knock-
down on NUMB localization. Further, we observed that NUMB undergoes 
partial nuclear localization in presence of HMGA1 knock-down. This was 
confirmed by Western blot analysis of nuclear/cytoplasmic extracts. 
Therefore, altogether, these data suggest the existence of an HMGA1-NUMB-
p53 axis. Given, as previously discussed, the significant role of NUMB and 
p53 in the regulation of the asymmetric cell division and in the protection from 
CSCs formation, one could hypotesize that HMGA1 participates in these 
processes by increasing the CSCs self-renewal, either by directly acting on p53 
and NUMB or by enhancing their interaction in the nucleus through NUMB 
relocalization.  
The interaction between p53 and NUMB has been found implicated in 
chemoresistance. Indeed, NUMB overexpression increases p53 stability and 
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activity, and in MCF10A it has been found to correlate with an approximately 
three-fold higher level of activated caspase-3 in response to cisplatin-induced 
DNA damage (Colaluca et al. 2008). Deficient p53 activity is associated with 
resistance to the cytotoxic effects of chemotherapy. Thus, also NUMB showed 
an inverse correlation with chemoresistance in breast tumors. Further, re-
expression of NUMB in class 1 cells restored responsiveness to cisplatin to 
levels comparable to those of control class 3 cells. Accordingly, NUMB-
silencing in class 3 cells increased resistance to the drug to levels comparable 
to those of control class 1 cells (Colaluca et al. 2008). HMGA1 has been 
demonstrated to enhance chemoresistance in tumors by promoting ATM 
expression, or by regulating the Akt phosphorylation, leading to an increased 
resistance to apoptosis (Liau and Whang 2008; Palmieri et al. 2011). In 
agreement with these findings, we evaluated the cell proliferation after 
treatment with Gefitinib, a selective inhibitor of the tyrosine kinase receptor of 
epidermal growth factor (EGFR). We observed that HMGA1 knock-down 
sensitizes CTSCs to the drug; indeed, we achieved a cytotoxic effect at lower 
doses in CTSC_shA1 compared to CTSCs_ctrl. In addition, our preliminary 
data showed that CTSC_ctrl cells decreased for few days in their number, after 
treatment with cytotoxic doses of Gefitinib, but they regained normal 
proliferation after one week from the treatment. Conversely, in CTSC_shA1 
we observed a long-lasting cytotoxic effect. A possible explanation for this 
phenomenon is that, thanks to their self-renewal ability, resistant CSCs rapidly 
replace those that were destroyed by Gefitinib; this behaviour is at the basis af 
tumor recurrence. HMGA1 knock-down, instead, sensitizes CSCs to Gefitinib 
and restrains the CSCs self-renewal capacity, making the treatment more 
effective. These findings are of great importance, since targeting HMGA1 
could be a potent strategy in clinical practice to achieve cancer eradication at 
lower drug doses. 
Many questions await answers. It remains to be clarified how HMGA1 
modulates the asymmetric relocalization of NUMB. During mitosis, the 
Baz/Par6/aPKC complex directs the distribution of the cell-fate determinant 
and the aPKC phosphorylation is a foundamental step to release NUMB from 
the apical cortex and to relocalize it (Gomez-Lopez et al. 2014). One can 
postulate an involvement of HMGA1 in the regulation of the Baz/Par6/aPKC 
complex; for instance, it might be interesting to investigate whether HMGA1 
overexpression can inhibit aPKC phosphorylation, blocking the NUMB 
relocalization. Another open question to be solved is whether HMGA1 is able 
to directly interact with NUMB, and to enter in the three-complex  NUMB-
HDM2-p53. HMGA1, HDM2 and p53 are nuclear proteins and it has been 
demonstrated the direct interaction with p53 and its regulatory activity on 
HDM2. NUMB is in the cytoplasm, mostly associated to biomembranes. Since 
the presence of HMGA1 regulates the NUMB relocalization in the nucleus, 
one could hypotesize an indirect effect of HMGA1 on its localization by 
regulating other effectors that promote the NUMB relocalization. For instance, 
it has been found that mdm2, which is regulated by HMGA1, can associate 
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with NUMB promoting its relocalization in the nucleus (Juven-Gershon et al. 
1998). Further, it is known that post-translational modifications have great 
importance for NUMB activity. Recently, the lysine methyltransferase Set8 has 
been found to inhibit the NUMB-p53 interaction and NUMB-mediated 
apoptosis by methylating NUMB. Doxorubicin promotes apoptosis and reduces 
the mRNA and protein levels of Set8. Thus, targeting Set8 or a NUMB 
demethylase may prove an effective strategy for cancer treatment (Dhami et al. 
2013). Our preliminary data showed that in BTSCs the HMGA1 silencing 
causes decreased mRNA levels of Set8, so we can postulate another molecular 
mechanism by which HMGA1 could regulate NUMB activity and localization 
by modulating its post-translational modifications. 
In conclusion, on the basis of the results shown here, indicating the cancer 
specific expression of HMGA1 and its peculiar role in CSCs, HMGA1 
targeting may represent a promising CSC-specific anti-cancer therapy. 
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6. CONCLUSIONS 
 
 
Several studies provide evidence that HMGA1 has an important role in the 
neoplastic transformation and it is causally involved in carcinogenesis. In 
recent years HMGA1 has also emerged as stemness factor, since it is able to 
regulate the self-renewal of ESCs; further its expression in adult tissues 
contributes to the maintainance of a "stem-like" state. 
The aim of our study has been to clarify the importance of HMGA1 in CSCs, 
which are the real tumor initiating cells, emerging as election targets for cancer 
eradication. We focused on colon tumor stem cells (CTSC) as a model for our 
study and we demonstrated that: 
 
 HMGA1 expression was higher in CTSCs compared to cancer cell lines 
and samples of tumoral and normal mucosa; the correlation with 
stemness is confirmed by the finding that, in CD133+ CTSCs, HMGA1 
expression was higher than in CD133- CTSCs. 
 
 HMGA1 has a pivotal role in CTSCs self-renewal and its silencing 
increases stem cell quiescence.  
 
 The silencing of HMGA1 decreases the sphere forming efficiency 
(SFE) and leads to an asymmetric distribution of NUMB, indicating 
that HMGA1 is able to influence the choice between symmetric and 
asymmetric divisions. 
 
 HMGA1 is able to transcriptionally repress NUMB and p53, which are 
known to regulate the asymmetric cell division.  
 
 All together, these data suggest that HMGA1 regulates the division 
pattern of CSCs by modulating the expression and/or the localization of 
polarity and cell fate determinants. 
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Abstract 
 
High-mobility group A1 (HMGA1) proteins are architectural chromatinic proteins, abundantly 
expressed during embryogenesis and in most cancer tissues, but expressed at low levels or absent in 
normal adult tissues. Several studies have demonstrated that HMGA1 proteins play a causal role in 
neoplastic cell transformation. The aim of this study was to investigate the role of these proteins in 
the control of cancer stem cells (CSCs), which have emerged as a preferred target in cancer therapy, 
because of their role in cancer recurrence. We observed that HMGA1 is overexpressed in colon 
tumour stem cell (CTSC) lines compared to normal and colon cancer tissues. We demonstrated that 
HMGA1 silencing in CTSCs increases stem cell quiescence and reduces self-renewal and sphere-
forming efficiency (SFE). The latter, together with the upregulation and asymmetric distribution of 
NUMB, is indicative of the recovery of an asymmetric division pattern, typical of normal stem 
cells. We further found that HMGA1 transcriptionally regulates p53, which is known to control the 
balance between symmetric and asymmetric divisions in CSCs. Therefore, our data indicate a 
critical role for HMGA1 in regulating both self-renewal and the symmetric/asymmetric division 
ratio in CSCs, suggesting that blocking HMGA1 function may be an effective anti-cancer therapy. 
 
 
Introduction 
 
Cancer arises from a small set of stem cells, or tumour-initiating cells, that differ from normal stem 
cells in their deregulated self-renewal and differentiation programs (1). Chemotherapy improves the 
5-year survival of adult cancer patients by only 2.3% in Australia and 2.1% in the USA (2). 
Surrogate end point parameters such as 'progression-free survival,' 'disease-free survival,' or 
'recurrence-free survival' reflect the temporary pause in the progression of the disease, seldom 
lasting more than a few months. Subsequently, the cancer typically returns with even more 
aggressive characteristics due to a few tumour-founding cells (the cancer stem cells or CSCs), 
which, because of their intrinsic chemoresistance, are spared and “naturally selected” by the 
routinely used anti-cancer drugs. This common trend makes the identification of CSC-specific 
targets and tightly related CSC-specific drugs necessary for the development of new effective anti-
cancer therapies.   
The High-Mobility Group A (HMGA) family includes three proteins: HMGA1a, HMGA1b, and 
HMGA2. These proteins are encoded by two distinct genes; the HMGA1a and HMGA1b proteins 
are products of the same gene through alternative splicing (3). The HMGA proteins bind the minor 
groove of AT-rich DNA sequences through their DNA binding domains, the so-called “AT-hooks.” 
HMGA proteins do not exhibit transcriptional activity per se, but they regulate the activity of 
several genes by interacting with the transcription machinery and altering the chromatin structure 
(4). The levels of HMGA proteins are low or absent in normal cells and adult tissues but are 
elevated in many tumours, neoplastically transformed cells, and embryonic cells (4). Their 
overexpression is largely associated with a highly malignant phenotype and also represents a poor 
prognostic marker, as HMGA overexpression often correlates with the presence of metastasis and 
reduced survival (5). Moreover, several studies indicate a causal role for HMGA gene expression in 
the process of carcinogenesis. Indeed, it has been reported that the blockage of their expression 
prevents thyroid cell transformation and promotes the death of malignant cells (6-7). Transgenic 
mice overexpressing either HMGA1 or HMGA2 develop uterine tumours, haematopoietic tumours, 
and pituitary adenomas (8-11). 
The observation of HMGA1 upregulation in colon cancer dates back to 1996, when our group 
detected the HMGA1 proteins, previously called HMGI(Y), in human colorectal cancer cell lines 
and tissues but not in normal intestinal mucosa (12). Subsequently, we reported that HMGA1 
protein expression was associated with the early stages of the neoplastic transformation of colon 
cells but only rarely with colon cell hyperproliferation (13), closely correlating with the degree of 
cellular atypia in adenomas. Very recently, Belton and colleagues (14) reported that HMGA1 
overexpression induces cell proliferation and polyp formation in the intestines of HMGA1 
transgenic mice and leads to metastatic progression and stem cell-like properties in colon cancer 
cells (14), suggesting that HMGA1 is a key regulator both in metastatic progression and in the 
maintenance of a stem cell-like state (14). Therefore, the aim of our studies was to investigate the 
role of the HMGA proteins in colon cancer stem cells by silencing their expression.  
Here, we report that HMGA1 silencing dramatically affects the survival of colon tumour stem cells 
and shifts stem cell division to an asymmetric pattern. The ability of HMGA1 to negatively regulate 
p53 promoter activity at the transcriptional level at least partially accounts for the effects induced 
by its inhibition on CTSCs.  
 
 
Results 
 
HMGA1 is overexpressed in CTSCs and in the CD133+ sub-population 
We first analysed HMGA1 expression by Western Blot in normal colonic mucosa (NM), colon 
cancer, colon cancer cell lines, and CTSC lines. As shown in Figure 1A, HMGA1 was undetectable 
in NM, whereas it was expressed in colon cancer (Tumour #3), in 3 colon cancer cell lines (SW48, 
SW480 and CACO2), and CTSCs (CTSC#18 and CTSC#1.1), which exhibited the highest HMGA1 
expression (Figure 1B). Interestingly, when CTSCs were stained for the cancer stem cell marker 
CD133 and then sorted, HMGA1 expression was enriched in CD133+ cells (Figure 1B). These data 
indicate that HMGA1 is overexpressed in CTSCs and is more abundant in stem cells than in 
precursors.  
 
HMGA1 knockdown impairs CTSC growth and induces apoptosis 
To understand the role of HMGA1 in CTSC, we silenced HMGA1 expression in the CTCS#18 cell 
line, using a short hairpin interfering construct (see the Materials and Methods section), leading to 
an HMGA1 knockdown efficiency of approximately 50%-80% in stable transfectants (Figure 2A). 
Growth curves performed on single-cell suspensions demonstrated that the knockdown of HMGA1 
significantly reduced CTSC proliferation (p < 0.05) (Figure 2B). The analysis of cell cycle 
progression, performed by flow cytometric analysis, demonstrated that HMGA1 knockdown 
reproducibly altered cell cycle progression, inducing a mean increase of 5% in the G1 phase 
population and a concomitant mean reduction of 4% in the S phase (Figure 2C). As previously 
reported (Shah et al., 2012), HMGA1 knockdown reduced the expression of stem cell/pluripotency 
genes, such as SOX2 and NANOG (Figure 2D). 
Because the alteration of the cell cycle only partially accounts for the reduction in CTSC 
proliferation induced by HMGA1 knockdown, we investigated apoptotic cell death. TUNEL 
(terminal deoxynucleotidyl transferase dUTP nick-end labeling) assays performed on stable 
transfectants exhibited a 7-fold increase in apoptotic cell numbers in CTSC_shA1 with respect to 
control cells (Figures 3A and B). These data suggest that, as in other cell systems (4), HMGA1 
plays a key role in CTSC proliferation by affecting cell cycle progression and apoptosis.  
 
HMGA1 silencing impairs CTSC self-renewal and sphere-forming efficiency in serial 
passages 
CTSCs, as other types of cancer stem cells, are characterised by their ability to form spheres in 
suspension cultures (15) or in a semisolid medium. The number of spheres reflects the quantity of 
cells capable of in vitro self-renewal, whereas the number of cells/sphere measures the self-renewal 
capacity of each sphere-generating cell (16). Therefore, we assayed the ability of cells with reduced 
HMGA expression to form spheres in methylcellulose-based medium. A dramatic reduction in the 
number of spheres (Figure 4A) and in their diameter (Figure 4B) was observed in CTSC_shA1 cells 
compared with control CTSC_ctrl, thus indicating that HMGA1-interference affects CTSC self-
renewal.  
CSCs are known to differ from normal stem cells both in their deregulated self-renewal and cell 
division pattern, and an evaluation of their sphere-formation efficiency (SFE) in serial passages 
allows the assessment of the rate at which CSCs divide symmetrically (16-17). As shown in Figure 
4C, the SFE of CTSC_shA1 cells decreased at every passage, whereas the number of spheres 
derived from parental (not shown) or CTSC_ctrl cells increased progressively. Interestingly, 
previous studies have demonstrated that the knock-out of p53 leads to increases in SFE and the 
symmetric division of mammary stem cells in serial passages, whereas the p53 stabiliser Nutlin-3 is 
able to reduce the SFE of ErbB2 mammary stem cells in serial passages (18). Consistent with these 
studies, we observed that the treatment of parental CTSC#18 with 5 µM Nutlin-3 was able to 
maintain the SFE over subsequent passages (Figure 4C, lower panel), similar to what was observed 
for CTSC_shA1 cells. Conversely, SFE increased in DMSO-treated cells (Figure 4C, lower panel). 
Therefore, these results indicate that HMGA1 silencing not only restores the ability to divide 
asymmetrically but also exhibits a more dramatic effect than p53 stabilisation alone.  
 
HMGA1 silencing induces quiescence and the asymmetric distribution of Numb in CSCs  
Long-term label retention of PKH26 dye is frequently used as an indicator of normal stem cell 
quiescence (19). Indeed, rapidly and symmetrically dividing CSCs tend to quickly lose PKH26 
(18), which irreversibly binds to the lipid bilayers on cell membranes and is equally distributed 
among daughter cells during each cell division. Conversely, normal quiescent stem cells divide 
asymmetrically in one proliferating progenitor and one self-renewing PKH26-retaining quiescent 
stem cell. Therefore, we stained CTSC_shA1 and control CTSC_ctrl cells with PKH26 and 
performed a FACS analysis after 10 days. As shown in Figure 5A, knockdown of HMGA1 
expression led to a drastic increase in PKH26bright cells (1.5 % in CTSC_ctrl cells versus 4.8 % in 
CTSC_shA1 cells) (Figure 5A), suggesting that the reduction in HMGA1 expression confers 
properties of quiescence to the stem cell compartment. Interestingly, very similar results were 
obtained when HMGA1-knockdown brain tumour stem cells (BTSCs) were stained with PKH26 
(Colamaio et al., manuscript in preparation).  
Asymmetric cell division can be demonstrated by the asymmetric partitioning of the cell fate 
determinant Numb (19). During asymmetric cell division, the part of the cell that inherits high 
levels of Numb will undergo differentiation, whereas the part that inherits low levels will produce a 
stem cell (20); conversely, in symmetrically dividing CSCs, Numb is expressed at lower levels and 
is uniformly distributed in such a way that both daughter cells will be equal in terms of Numb 
expression and function (20).  
Therefore, we analysed Numb expression/distribution in HMGA1-knockdown and control cells. 
Western blot analysis for Numb revealed higher levels of Numb in CTSC_shA1 cells with respect 
to untransfected and CTSC_ctrl cells (Figure 5B). Moreover, immunofluorescence of the spheres 
(Figure 5C) demonstrated that whereas Numb was distributed almost uniformly in the cell 
cytoplasm of CTSC_ctrl cells, it formed an asymmetric punctuate crescent close to the cell 
membrane (Figure 5C, right panels, arrows) in CTSC_shA1 cells, where it also undergoes partial 
nuclear localisation (asterisks). The frequency of Numb crescents increased from approximately 6% 
in control cells, to approximately 32% in CTSC_shA1 cells (p = 0,0048) (Figure 5C, right panel). 
Together, these data demonstrate that HMGA1-silencing restores normal stem cell properties in 
CSCs, such as quiescence and asymmetric division. 
 
HMGA1 regulates p53 expression at the transcriptional level 
Because it has been previously shown that an imbalance between asymmetric and symmetric 
division can be determined by loss of the p53 tumour suppressor (18), we analysed p53 expression 
in CTSC_shA1 cells. Western blots performed on untransfected, scramble-transfected, and 
HMGA1–knockdown CTSCs demonstrated that the downregulation of HMGA1 increased p53 
protein expression (Figure 6A, upper panel) and was associated with an increase in the p53-
regulated p21 protein (Figure 6A, lower panel), indicating the presence of a functional p53. 
Subsequently, to assess the direct action of HMGA1 on p53 transcription, we evaluated HMGA1 
protein binding to the p53 promoter in vivo by performing ChIP assays. Therefore, CTSC_ctrl and 
CTSC_shA1 cells were cross-linked and immunoprecipitated with anti-HMGA1 or anti-IgG 
antibodies. Immunoprecipitation of chromatin was then analysed by quantitative PCR, using 
primers spanning 5 different regions of the p53 promoter (see the Materials and Methods section). 
Occupancy of the p53 promoter regions II and III by HMGA1 was clearly detectable (Figure 6B), 
whereas no amplification was observed in regions I, IV, and V, indicating the specificity of the 
binding to regions II and III (Figure 6B). Conversely, CTSC_shA1 cells exhibited a negligible 
enrichment for regions II and III (Figure 6B) and no enrichment at all for the remaining regions. 
These results indicate that HMGA1 protein binds the p53 promoter region in vivo. 
Finally, to define the functional importance of HMGA1 binding to the p53 promoter, we evaluated 
the activity of the p53 promoter in the presence or absence of HMGA1 by performing luciferase 
assays. Therefore, HEK293 cells were transfected with a reporter gene construct carrying the 
human p53 promoter (21) or a control backbone vector (pGL3-basic) in the presence of an 
HMGA1-expressing construct. As shown in Figure 6C, HMGA1 repressed the p53 promoter, and 
this effect was dose-dependent. Consistently, this repressive effect was abolished by the 
pharmacological blocking of the HMGA1-DNA interaction with distamycin (not shown), a drug 
known to displace HMGA1 from its AT-rich DNA regions (22). Therefore, these results clearly 
demonstrate that HMGA1 transcriptionally regulates p53 expression.  
Discussion  
CSCs are a distinct subset of cancer cells with the ability to self-renew through symmetric division 
and to generate a repertoire of various cell types, thus initiating and perpetuating tumour growth. 
CSCs are often endowed with distinctive surface markers, such as CD133, which, in colon cancer 
and in gliomas and other cancers, decorates tumour-initiating cells versus cells that are unable to 
initiate tumours in transplantation experiments (23). In human cancers, CSCs have been 
demonstrated to be a major cause of cancer treatment resistance, invasion, metastasis, and relapse. 
Thus, eliminating cancer cells with stem cell properties is of prime importance for the successful 
treatment of cancer, regardless of the tissue of origin.   
Recent studies have suggested the critical role of the HMGA1 protein as a master regulator in both 
cancer stem cells (14; 24) and normal embryonic stem cells (25; 24). Indeed, HMGA1 has recently 
been shown to reprogram somatic cells into pluripotent stem cells by inducing stem cell 
transcriptional networks (26). Moreover, several studies have directly or indirectly demonstrated 
that HMGA proteins are tightly associated with stemness and play a critical role in the epithelial-
mesenchymal transition (EMT) (27). 
Here, we present data unveiling a central role for HMGA1 in CSC self-renewal. First, we 
demonstrated that HMGA1 is enriched in CTSCs compared with colon tumours and cancer cell 
lines and is more abundantly expressed in CD133+ cells than in CD133- cells, strengthening its 
association with tumour-initiating cells. 
Next, we demonstrated that the knockdown of HMGA1 by antisense methodology in colon CSCs 
induces a drastic reduction in cell proliferation due to a slight increase in the G1 phase population 
and a more evident increase in apoptosis, consistent with our previous findings (7). Moreover, 
CTSC_shA1 cells regain two properties typical of normal adult stem cells: an increased percentage 
(and brightness) of PKH26-positive cells, which indicates increased quiescence, and reduced SFE, 
suggestive of the recovery in asymmetric division at the expense of symmetric self-renewing 
division (17). This shift in the division modality, induced by the depletion of HMGA1 in CSC cells 
might be of practical clinical relevance because asymmetric division plays a tumour-suppressive 
role (20). Notably, we have achieved comparable results, in terms of SFE reduction and PKH26 
increase, in HMGA1-knockdown BTSCs (Colamaio et al., manuscript in preparation), suggesting 
the critical role of the HMGA1 protein in the regulation of CSCs of different tissue origin.  
Recently, it has been demonstrated that ErbB2 transgenic mice harbour CSCs with an increased 
frequency of self-renewing divisions, higher replicative potential, and a preponderance of 
symmetric versus asymmetric division, highlighted by the symmetric distribution of the cell fate 
determinant Numb, compared with stem cells from wild-type mice (18). In these cells, Nutlin 3-
mediated stabilisation of p53 was able to restore asymmetric division (as evidenced by the recovery 
of the asymmetric distribution of Numb) (18). The striking similarity of the phenotype obtained in 
CTSC_shA1 with Nutlin-3 treated CSCs and the tight association of HMGA1 and ErbB2 
expression (28) prompted us to investigate the effect of HMGA1 interference on the p53-Numb 
axis. Indeed, we demonstrated that in CTSC_shA1 cells, the expression levels of both p53 and its 
downstream target p21cip are increased with respect to control cells. Moreover, we demonstrate 
that HMGA1 directly binds to a discrete region in the p53 promoter, and this binding has functional 
consequences, leading to p53 transcriptional downregulation. 
It is worth noting that HMGA1 overexpression may lead to p53 inactivation by other mechanisms, 
such as through interfering with p53-mediated transcription of the p53 effectors Bax and p21 (29), 
transcriptionally activating the p53 inhibitor mdm2, and cytoplasmically relocalising its 
proapoptotic activator HIPK2 (30; 4). Therefore, the restoration of p53 functions exerted by 
HMGA1 knockdown likely accounts for the effects of HMGA1 silencing on CSC cells.  
However, we cannot exclude the possibility that in addition to a p53-mediated mechanism, HMGA1 
silencing might affect CSCs through other mechanisms. In fact, we have demonstrated that whereas 
the SFE of Nutlin-3-treated CTSCs remains constant overtime, the SFE of HMGA1-knockdown 
cells progressively decreases in serial passages.  
Consistent with the data of Cicalese, the increased expression of NUMB was also observed in 
CTSC_shA1 concomitant with the nuclear relocalisation of the protein (F. Puca, unpublished 
preliminary results). The increased expression of NUMB would also enhance the stabilisation of 
p53 (31). Therefore, taken together, these data suggest the existence of an HMGA1-Numb-p53 axis 
in which HMGA1 could play a significant role in regulating self-renewal either by directly acting 
on p53 and NUMB or by enhancing their interaction in the nucleus. In conclusion, the results 
presented herein indicate that HMGA1 has a specific role in CSC self-renewal, and thus, targeting 
HMGA1 may represent a promising CSC-specific anti-cancer therapy strategy. 
  
Materials and methods 
 
Cell cultures and culture conditions 
Colon tumour stem cell lines were kindly donated by Prof. Ruggero De Maria (Istituto Superiore di 
Sanità, Rome, Italy) and have been described elsewhere, together with their culturing conditions 
(15). Cytokines added to the medium included recombinant human FGF-basic and EGF (Peprotech, 
Rocky Hill, NJ). HEK293 cells were maintained in DMEM medium containing 10% fetal calf 
serum (Invitrogen). 
 
Colon samples  
Normal and cancerous intestinal mucosa samples were kindly provided by Dott. Marina De Rosa 
(Facoltà di Medicina e Chirurgia, University “Federico II”, Naples, Italy) and have been described 
elsewhere (32).  
 
Quantitative reverse transcription PCR (qRT-PCR) 
Total RNA was reverse transcribed using the QuantiTect Reverse Transcription Kit (Qiagen), and 
qRT-PCR was performed by using Power SYBR Green PCR Master Mix (Applied Biosystems, 
Foster City, CA, USA) according to manufacturer’s instructions. G6PD was used to normalise 
RNA levels. The primers used were as follows: Hsa_HMGA1_Fw: 5’-
CAACTCCAGGAAGGAAACCA, Hsa_HMGA1_Rev: 5’-AGGACTCCTGCGAGATGC; 
Hsa_G6PD_Fw: 5’-ACAGAGTGAGCCCTTCTTCAA, and Hsa_G6PD_Rev: 5’-
ATAGGAGTTGCGGGCAAAG; SOX2_Fw: 5’- GCACATGAACGGCTGGAGCAACG; 
SOX2_Rev: 5’- 
TGCTGCGAGTAGGACATGCTGTAGG; NANOG_Fw: 5’- CAAAGGCAAACAACCCACTT; 
NANOG_Rev: 5’- TCTGGAACCAGGTCTTCACC. The 2–ΔΔCt formula was used to calculate the 
differential gene expression. 
 
Immunostaining and cell sorting 
For cell sorting, the cells were trypsinised, washed twice with PBS, and incubated with anti-human 
CD133 (CD133/2 (293C3)-PE, Miltenyi Biotech) for 20 minutes at 4°C. After washing twice with 
PBS, the cells were FACS sorted with a FACScan flow cytometer (Becton Dickinson, San Jose, 
CA) interfaced with a Hewlett-Packard computer (Palo Alto, CA).  
 
Western blots and antibodies 
Total protein extraction, western blotting, and anti-HMGA1 antibodies have been described 
elsewhere (33). 
The following other antibodies were used: anti-GAPDH (Santa Cruz Biotechnology, CA, USA) and 
anti-p21 (Cell Signaling Technology, Inc.,Danvers, MA). Anti-Numb antibodies were obtained 
from Abcam (Cambridge, UK) and were used at 1:5000. Blots were visualised using western 
blotting detection reagents (GE Healthcare, Buckinghamshire, UK). 
 
Plasmids 
The hairpin RNA interference plasmid for human HMGA1 (pLKO.1-HMGA1, TRCN0000018949) 
and the scramble control pLKO.1-Puro plasmid (SHC002) were obtained from Sigma-Aldrich. The 
sequence of the short hairpin RNA targeting the human HMGA1 gene was 5′–
CCGGCAACTCCAGGAAGGAAACCAACTCGAGTTGGTTTCCTTCCTGGAGTTGTTTTT–3′, 
(shHMGA1 targets coding region positions 446-466 of HMGA1 mRNA transcript variant 2).  
The pGL3-luci vector containing the p53 promoter was kindly provided by Prof. David Reisman 
(Center for Colon Cancer Research Tissue Repository, University of South Carolina, Columbia) 
(21). 
The pCDNA3.1-HMGA1 expression vector has been described previously (25). 
 
Transfections  
CTSCs were electroporated using the Neon® Transfection System (Invitrogen). Cells were 
trypsinised with TrypLE™ Express (GIBCO) and counted; 1 x 106 cells were subjected to the 
electric field (1400 V, 20 msec; 1 pulse). After 48 h, CTSCs transfected with the short hairpin-
expressing constructs were selected with puromycin (2 µg/µl).  
 
Growth curves and TUNEL assay 
Approximately 5 x 103 stably transfected cells were plated in 96-well plates. Cells were counted in 
triplicate at daily intervals with a Burker hemocytometer chamber. 
A TUNEL assay was performed using the In Situ Cell Death Detection kit (Roche) according to 
manufacturer’s instructions. 
 
Flow cytometry 
After trypsinisation, the cells were washed in PBS and fixed in 70% ethanol. Staining for DNA 
content was performed with 0.1% NP-40, 50 µg/ml propidium iodide, and 25 µg/ml ribonuclease A 
for 20 min. For each measurement, 10,000 events were analysed. We used a FACScanto II flow 
cytometer (Becton Dickinson, San Jose, CA). Cell cycle data were analysed with the ModFit LT 2.0 
software (Verity Software) in a semiautomatic analysis procedure. Briefly, we manually selected 
the cell population in an FSC versus SSC dot plot and discarded debris, and then we gated single 
cells in a PI-height versus PI-area dot plot, excluding all doublets. The MODFIT algorithm was 
used to analyse our files, calculating the percentages of cells in each cell cycle phase.  
 
Sphere formation assays  
Sphere-forming assays in methylcellulose-based medium were performed as previously described 
(34) with some modifications. Briefly, medium containing 0.8% methylcellulose was used instead 
of liquid medium, and other conditions were the same as in liquid medium. Three percent 
methylcellulose was purchased from R&D Systems (Minneapolis, USA), and a stock solution was 
made of 2% methylcellulose in DMEM⁄F12. A final concentration of 0.8% methylcellulose in 
DMEM⁄F12 was used for cell culture. Approximately 2 x 104 cells from disaggregated CTSC 
spheres were resuspended in a semisolid medium and plated in 6-well plates. After 7 days, the 
spheres were microscopically visualised, and the diameters were measured.  
Serial passage experiments were conducted as described previously (18) with some modifications. 
Briefly, 5,000 cells from disaggregated CTSC spheres were plated on 150-mm poly-HEMA-treated 
cell culture plates. After 10 days, the spheres were disaggregated and re-plated at the same density. 
The sphere-forming efficiency (SFE) at each passage was obtained by calculating the percentage of 
the number of spheres divided by the number of cells plated.  
 
PKH staining and flow cytometric analysis 
PKH staining was performed as previously described (19). 
CTSCs were trypsinised, filtered through a 40-μm cell strainer, resuspended in PBS (approximately 
500,000 cells/ml), labelled with PKH26 (Sigma, 10−7 M, 5 min), washed twice, and plated.  
For the flow cytometric analysis of PKH26-stained cells, CTSCs were trypsinised, filtered through 
a 40-μm cell strainer, and resuspended in PBS at a concentration of 1x106/ml. The cells were 
subdivided into 5-ml polystyrene tubes (Falcon, Becton Dickinson). The BD FACSAria cytometer, 
equipped with four excitation laser lines (633 nm, 488 nm, 405 nm, and 375 nm) (Becton 
Dickinson) was used for FACS analysis, and the BD FacsDIVA software was used for data 
analysis. 
PKH26 staining was evaluated by selecting the appropriate cell population according to the 
following gating strategy: (i) cells were first gated on physical parameters (forward scatter [FSC] 
and side scatter [SSC]) to exclude most of the debris and dead cells; (ii) doublets and aggregates 
were eliminated using the FSC-area vs. FSC-height pattern. We gated 10-15% of the brightest 
PKH26+ cells in a PKH26 versus empty channel dot plot.   
 
Immunofluorescence 
Whole spheres were centrifuged and fixed with 4% paraformaldehyde, permeabilised, with 0.1% 
Triton X-100 and 3% BSA, and stained with anti-Numb (kindly donated by Prof. Salvatore Pece 
and previously described (18), followed by anti-mouse Alexa 488 (Jackson ImmunoResearch 
Europe Ltd., Suffolk, UK) antibodies. Confocal analysis was performed with a Leica TCS SP2 
AOBS microscope.  
 
Luciferase assay 
Transfections for luciferase assays were performed in HEK293 cells using the Lipofectamine 2000 
method (Invitrogen S.r.l., S. Giuliano Milanese, MI, Italy). Approximately 2 × 105 cells were 
transiently transfected with 200 ng of pGL3-luci vector containing the p53 promoter (kindly 
provided by Professor David Reisman, Center for Colon Cancer Research Tissue Repository, 
University of South Carolina, Columbia) and with the indicated amounts of the pCDNA3.1-
HMGA1 expression vector or the corresponding empty vector together with 0.5 μg of Renilla. 
Various amounts of the pCDNA3.1 plasmid were co-transfected to keep the total DNA 
concentration constant. Transfection efficiencies were normalised using Renilla luciferase 
expression assayed with the dual luciferase system (Promega Italia, Milan, Italy). All transfection 
experiments were performed in duplicate.  
 
Chromatin immunoprecipitation 
ChiP was performed as described previously (35). As a negative control, ChIP experiments were 
performed with isotype-matched preimmune IgG. The promoter occupancy was calculated with 
respect to the input as the percentage of anti-A1-immunoprecipitated DNA subtracted from the IgG-
immunoprecipitated DNA. The P53 promoter regions assayed for HMGA1 binding refer to the 
nucleotide sequence previously published (21) and are indicated as follows: Region I: nt 401-557; 
region II: nt 538-650; region III: nt 631-751; region IV: nt 767-890; and region V: nt 989-1090. 
The primers for each region were as follows:  
Prom_hQ_tp53_1_F: 5’-CAGGCTTCAGACCTGTCTCC 
Prom_hQ_tp53_1_R: 5’-GCTTTCAGTACATGGAAACGTAA 
Prom_hQ_tp53_2_F: 5’-CGTTTCCATGTACTGAAAGCAA 
Prom_hQ_tp53_2_R: 5’-CCCTAACGTTTTCTCCCAGA 
Prom_hQ_tp53_3_F: 5’-TCTGGGAGAAAACGTTAGGG 
Prom_hQ_tp53_3_R: 5’-AAGGGTGGAAGGAAGAAAGC 
Prom_hQ_tp53_4_F: 5’-GCAGGATTCCTCCAAAATGA 
Prom_hQ_tp53_4_R: 5’-GAGGGTGCAGAGTCAGGATT 
Prom_hQ_tp53_5_F: 5’-GTTGATGGGATTGGGGTTTT 
Prom_hQ_tp53_5_R: 5’-AGCTACCTGCTCCCTGGAC 
Prom_GAPDH_1F: 5’-CCCAAAGTCCTCCTGTTTCA 
Prom_GAPDH_R: 5’-GTCTTGAGGCCTGAGTACG 
 
Statistical analysis 
Statistical analyses were performed using the Kruskal-Wallis test or the Mann-Whitney U-test. If 
the Kruskal-Wallis test was positive (p < 0.05), a pairwise comparison of subgroups was performed 
using Dunn's post-hoc test. 
 
Figure 1 
HMGA1 expression in CTSCs 
A) Western blot for HMGA1 in normal colonic mucosa (NM), colon cancer sample (T#3), colon 
tumour-derived cell lines, SW48, SW480, GEO, and CACO3, and colon tumour stem cells 
(CTSC#18 and CTSC#1.1). B) Western blot for HMGA1 in unsorted CTSC#18 and sorted CD133+ 
and CD133- cells. GAPDH was used as a loading control.  
Figure 2 
HMGA1 knockdown affects the proliferation and cell cycle of CTSCs. A) Western blots for 
HMGA1 in untransfected, HMGA1-knockdown (CTSC_shA1), and scramble-transfected 
(CTSC_ctrl) cells. GAPDH is used as a loading control. B) Growth curve of stable scramble 
(CTSC_ctrl) and HMGA1-knockdown (CTSC_shA1) CTSCs. Data are the mean value ± SD of one 
representative experiment, performed in quadruplicate (*, p < 0.05, Mann-Whitney U-test). C) 
Histogram of the FACS analysis in CTSC_ctrl and CTSC_shA1 cells. Data are the mean value ± 
SD of 3 independent experiments. D) qRT-PCR for SOX2 and NANOG gene expression in 
CTSC_ctrl and CTCS_shA1 cells. The expression level of each gene was normalized to the G6PD 
gene expression (*, p < 0.05, Mann-Whitney U-test). 
Figure 3 
HMGA1 knockdown effects on apoptosis in CTSCs.  
A) Fluorescence micrographs of TUNEL assays performed on non-transfected CTSCs (CTSC_NT), 
CTSC_ctrl and CTSC_shA1 cells, double-stained with Hoechst dye (left) to identify total nuclei 
and with TMR red UTP (right) to identify apoptotic, TUNEL-positive cells. B) Bar chart 
representation of the number of TUNEL-positive cells per 100 Hoechst-positive nuclei in the 
samples shown in A. Each bar represents the mean ± SD of 10 arbitrary fields. An asterisk indicates 
the significance of the difference between CTSC_shA1 and CTSC_ctrl (*, p = 0.0014; Kruskal-
Wallis test followed by Dunn's post-hoc test). 
Figure 4 
Effects of HMGA1 knockdown on the sphere-formation ability of CTSCs.  
A) The diagram represents the average number of spheres in the methylcellulose-based medium 
after 7 days. Spheres with diameters > 70 µm were counted in each of 10 representative fields. 
Triple asterisks indicate the significance of the difference in the number of spheres formed by 
CSC_ctrl and CTSC_shA1 cells (***, p < 0.0001; Mann-Whitney U-test). 
B) Diagram showing the sphere diameter distribution in CTSC_ctrl and CTSC_shA1 cells. Each bar 
represents the mean ± SD diameter found in 10 representative fields. Mann-Whitney U-test. C) 
Diagram showing the sphere-formation efficiency (SFE) ± SD in scramble- and HMGA1-
knockdown CTSCs in serial passages (from F0 to F3). The spheres were disaggregated every 10 
days. SFE is measured as the percentage of the number of spheres per plated cell at every passage. 
The data represent the results of two independent experiments.  
D) Sphere-formation efficiency (SFE) in parental CTSC#18 cells treated with DMSO or Nutlin-3 (5 
μM) in serial passages (from F0 to F3). Spheres were disaggregated every 7 days. The data 
represent the mean value ± SD of two independent experiments.  
Figure 5 
HMGA1 knockdown induces stem cell quiescence and asymmetric Numb distribution. 
A) FACS plots of double-coloured (PKH26-phycoerythrin [PE] and fluorescein isothiocyanate 
[FITC-A]) CTSC_ctrl and CTSC_shA1 cells (one representative experiment). The left-most panel 
shows cells non-stained with PKH26, gated on physical parameters (forward scatter [FSC] and side 
scatter [SSC]) to exclude most of the debris and dead cells.  
B) Mean percentage of PKH26bright cells in CTSC_ctrl and CTSC_shA1 populations, after 10 days 
from staining. Each bar represents the mean ± SD of 5 independent experiments (*, p < 0,05; Mann-
Whitney U-test). 
C) Western blot for Numb in non-transfected, CTSC_shA1, and CTSC_ctrl cells. GAPDH was 
used as a loading control.  
D) Immunofluorescence for Numb in CTSC_ctrl (left) and CTSC_shA1 (right) CTSCs. The nuclei 
are stained in blue with DAPI. Arrows denote the crescent-shaped Numb distribution whereas 
asterisks indicate nuclear-localised Numb. The histogram shows the percentage of cells with 
crescent-shaped, asymmetric Numb distribution, obtained in immunofluorescence analyses, as in 
C). Data are the mean value ± SD of 7 arbitrary fields for each sample. (** , p = 0.0048; Mann-
Whitney U-test). 
Figure 6 
HMGA1 negatively regulates p53 expression at the transcriptional level. 
A) Western blot analysis for p53 (upper panel) and p21 (lower panel) expression in non-transfected, 
HMGA1-knockdown, and scramble-transfected cells. GAPDH was used as a loading control.  
B) ChIP assay, revealed by qPCR, detecting the in vivo binding of HMGA1 to the 5 sub-regions in 
the p53 promoter in CTSC_ctrl and CTSC_shA1 extracts. The relative occupancy of the p53 
promoter regions by HMGA1 is indicated as vertical bars. GAPDH promoter amplicon was used as 
a negative control. 
C) Luciferase activity of the p53 promoter in HEK 293 cells in the presence or absence of an 
HMGA1-expressing vector. The amounts of the HMGA1-expressing vector are indicated. The data 
are the results of three independent experiments performed in duplicate. The relative luciferase 
activity was normalised with Renilla luciferase and was expressed as the fold induction over the 
activity of the p53 promoter (*, p < 0.05). pGL3-basic activity in the presence or absence of the 
HMGA1-expressing construct was used as a negative control.  
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